Document:

Sublicense Agreement

  
 EXHIBIT 10.72

 Portions of this exhibit marked [*] are requested to be treated confidentially. 

EXECUTION VERSION 
 Dated August 27 2010 
  

 
 Salix
Pharmaceuticals, Inc. 
 - and - 
 Norgine B.V. 
 Norgine Europe B.V. 

- and - 

Novel Laboratories, Inc. 
  

 
 SUBLICENSE
AGREEMENT 
 (Moviprep®) 
  

 

  
 THIS SUBLICENSE
AGREEMENT (this “Agreement”) is made the 27th day of August, 2010 (the “Execution Date”), between SALIX PHARMACEUTICALS, INC., a California corporation (“Sublicensor”); NORGINE
B.V. and NORGINE EUROPE B.V., both Dutch companies (together, “Norgine”); and NOVEL LABORATORIES, INC., a Delaware corporation (“Sublicensee”). In this Agreement, Sublicensor, Norgine and
Sublicensee are referred to together as the “Parties” and each is referred to as a “Party.” 

RECITALS 

WHEREAS, Sublicensor holds a license from Norgine in respect of the Norgine Patents (as defined herein); 

WHEREAS, Sublicensor desires to sublicense to Sublicensee, and Sublicensee desires to take a sublicense under, Sublicensor’s
rights in respect of the Norgine Patents, all on the terms and conditions set forth below; and 
 WHEREAS, Norgine
desires to license to Sublicensee, and Sublicensee desires to take a license under, Norgine’s rights in respect of the Norgine Patents, all on the terms and conditions set forth below; 

NOW, THEREFORE, in consideration of the mutual covenants contained in this Agreement, and other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, hereby agree as follows: 
  

	1.	Definitions 

 Unless
otherwise specifically provided herein, the following terms, when used with a capital letter at the beginning, shall have the following meanings: 
 1.1. “Actavis” means Actavis Inc., a Delaware corporation. 

1.2. “Affiliate” means, with respect to a Person, any Person that Controls, is Controlled by or is under common
Control with such first Person. For purposes of this definition only, “Control” means (a) to possess, directly or indirectly, the power to direct the 

 
management or policies of a Person, whether through ownership of voting securities, by contract relating to voting rights or corporate governance, or otherwise or (b) to own, directly or
indirectly, more than fifty percent (50%) of the outstanding voting securities, or other voting ownership interest, of such Person. 
 1.3. “Agreement” has the meaning set forth in the preamble hereto. 
 1.4. “Applicable Law” means the applicable laws, rules and regulations that may be in effect from time to time. 

1.5. “Approved Product” means the PEG product that is approved for distribution under New Drug
Application No. 021-881 as the same exists on the date hereof or may in the future be amended solely for the purpose of effecting non-material modifications to the product that is the subject thereof as of the date hereof so as to permit such
product to be marketed and sold in the Territory in compliance with Applicable Law and the requirements of Regulatory Authorities. 
 1.6. “Authorized Generic Product” means (a) any drug product containing PEG distributed under New Drug Application No. 021-881 but not under the trade name Moviprep® or (b) any Generic PEG Product that is sold in the Territory by a Third Party (other than Actavis or its
Affiliates) pursuant to a license or other authorization from Sublicensor or Norgine. 
 1.7. “Business
Day” means a day other than a Saturday or a Sunday on which banks in general in New York, New York are open for the conduct of normal commercial banking business at their counters. 

1.8. “Commercialize” means, in respect of a product, all activities relating to the importation, advertising,
promotion and other marketing of the product; pricing and reimbursement, Detailing, distribution, storage, and handling of the product; offering the product for sale and selling the product; and customer service and support in respect of the
product; in all cases, post-Marketing Authorization for the product. 

  
 2 

  
 1.9.
“Confidential Information” means (a) the existence and terms of this Agreement and (b) any and all information or material that, at any time before, on or after the Execution Date, has been or is provided or
communicated to the Receiving Party by or on behalf of the Disclosing Party pursuant to this Agreement or in connection with the transactions contemplated hereby or any discussions or negotiations with respect thereto, including any data, ideas,
concepts or techniques contained therein and any modifications thereof or derivations therefrom. Confidential Information may be disclosed either orally, visually, electronically, in writing, by delivery of materials containing Confidential
Information or in any other form now known or hereafter invented. 
 1.10. “Consent Judgment Entry Date”
has the meaning set forth in the Settlement Agreement. 
 1.11. “Courts” has the meaning set forth in
Section 7.3. 
 1.12. “Detailing” means face to fact contact between a field sales force
representative and a medical professional with prescribing authority for the purpose of discussing scientific or medical information about a pharmaceuticals product(s). 
 1.13. “Disclosing Party” shall mean the Party disclosing Confidential Information. 
 1.14. “Execution Date” has the meaning set forth in the first paragraph of this Agreement. 
 1.15. “Expiration Date” means the earlier of (a) the date of expiration of the later to expire of the Norgine Patents and (b) the date on which a court enters a final
decision from which no appeal has been or can be taken holding that all claims of the Norgine Patents that would otherwise be infringed by the making, having made, using, selling, offering for sale or importation of any Generic PEG Product are
unenforceable or invalid. 
 1.16. “FDA” means the United States Food and Drug Administration.

  
 3 

  
 1.17.
“Generic PEG Product” means a drug product containing PEG that refers to the Approved Product as the reference-listed drug in an Abbreviated New Drug Application or pursuant to an application under 21 U.S.C. § 355(b)(2).

 1.18. “Head License” means the License and Supply Agreement, dated December 7, 2005, as amended,
between Norgine and Sublicensor pursuant to which Sublicensor obtains its rights under the Norgine Patents. 
 1.19.
“Indemnification Claim Notice” has the meaning set forth in Section 4.2(a). 
 1.20.
“Indemnified Party” has the meaning set forth in Section 4.1. 
 1.21. “Injunction
Failure Date” means, in the event that (a) any Third Party other than Actavis or its Affiliates sells commercial-scale quantities of an Unlicensed Generic Product in the Territory prior to September 24, 2018, and
(b) Sublicensor fails to obtain a temporary restraining order or other preliminary injunctive relief enjoining the sale of such Unlicensed Generic Product in the Territory within [*] ([*]) Business Days following the date that Sublicensor
learns or is notified that such Third Party has sold such Unlicensed Generic Product (the “Knowledge Date”), then the date that is [*] ([*]) Business Days after the Knowledge Date, provided that notwithstanding the foregoing
the Injunction Failure Date shall be the date [*] ([*]) Business Days after the Knowledge Date if Sublicensor fails to pursue any such temporary restraining order or other preliminary injunctive relief in the applicable court within such
[*] ([*]) Business Day period. 
 1.22. “Knowledge Date” has the meaning set forth in
Section 1.21. 
 1.23. “Losses” means any and all direct or indirect liabilities, damages, losses
or expenses, including interest, penalties, and reasonable lawyers’ fees and disbursements. 

  
 [*] Confidential treatment
requested; certain information omitted and filed separately with the SEC. 
 4 

  
 1.24.
“Majority-Controlled Affiliate” (a) means, with respect to a Person, any Person that owns, directly or indirectly, more than fifty percent (50%) of the outstanding voting securities, or other voting ownership interest,
of such Person; any Person of which the first Person owns, directly or indirectly, more than fifty percent (50%) of the outstanding voting securities, or other voting ownership interest, of such Person; or any Person of which a Person owning,
directly or indirectly, more than fifty percent (50%) of the outstanding voting securities, or other voting ownership interest, of the first Person owns , directly or indirectly, more than fifty percent (50%) of the outstanding voting
securities, or other voting ownership interest, of such Person; and, (b) with respect to Sublicensee, includes GAVIS Pharmaceuticals, LLC. 
 1.25. “Marketing Authorization” means any approval required from a Regulatory Authority to market and sell a pharmaceutical product in any relevant territory including any form of
pricing or reimbursement approval. 
 1.26. “Norgine” has the meaning set forth in the first paragraph
of this Agreement. 
 1.27. “Norgine Patents” means United States patent number 7,169,381 and United
States patent number 7,658,914 and any divisions, continuations, continuations-in-part, re-examinations and reissues thereof. 

1.28. “Party” and “Parties” have the meanings set forth in the first paragraph of this
Agreement. 
 1.29. “PEG” means polyethylene glycol. 

1.30. “Person” means an individual, sole proprietorship, partnership, limited partnership, limited liability
partnership, corporation, limited liability company, business trust, joint stock company, trust, incorporated association, joint venture or similar entity or 

  
 5 

 
organization, including a government or political subdivision, department or agency of a government. 
 1.31. “Product” means the Generic PEG Product approved for distribution under the Sublicensee ANDA, provided that the formulation used to make such Generic PEG Product is
substantially similar to the formulation disclosed in the Sublicensee ANDA that was produced to Sublicensor and Norgine in discovery in the action that is the subject of the Settlement Agreement prior to the Execution Date and the Generic PEG
Product is sold under the Sublicensee ANDA. 
 1.32. “Receiving Party” shall mean the Party receiving
Confidential Information. 
 1.33. “Recipients” shall have the meaning set forth in Section 6.1.

 1.34. “Regulatory Authority” means any national, supranational, regional, state or local regulatory
agency, department, bureau, commission, council or other governmental entity, including the FDA, in any country. 
 1.35.
“Settlement Agreement” means that certain Settlement Agreement, dated the Execution Date, by and among the Parties and Actavis. 
 1.36. “Start Date” means the earliest of (a) September 24, 2018, (b) the date on which any commercial scale quantities of an Authorized Generic Product are sold in
the Territory, (c) the Injunction Failure Date, (d) the date on which a court enters a final decision from which no appeal has been or can be taken (other than a petition to the United States Supreme Court for a writ of certiorari) holding
that all claims of the Norgine Patents that would otherwise be infringed by the making, having made, using, selling, offering for sale or importation of Product in the Territory are unenforceable or invalid, and (e) the date on which the Supply
Agreement is terminated either by Sublicensor pursuant to Section 6.2(a)(i) or (c)(i) thereof or by Sublicensee and Actavis pursuant to Section 6.2(b) or by Sublicensee or Actavis pursuant to Section 6.2(c)(i) thereof if, as of such
date or within five (5) Business 

  
 6 

 
Days thereafter, Sublicensor has not (i) purchased and paid for at least the aggregate minimum quantities required to be purchased by it under Section 2.2(b)(i) and (ii) of the
Supply Agreement (or paid the aggregate applicable Per-Unit Supply Price (as such term is defined in the Supply Agreement) in respect of any Units (as such term is defined in the Supply Agreement) by which Salix’s purchases under the said
Section 2.2(b)(i) and (ii) have fallen short of the minimum quantities specified in the said sections) and (ii) made the payments required to be made by it pursuant to Section 2.9 of the Supply Agreement. 

1.37. “Sublicensee” has the meaning set forth in the first paragraph of this Agreement. 

1.38. “Sublicensee ANDA” means Sublicensee’s Abbreviated New Drug Application No. 90-145. 

1.39. “Sublicensor” has the meaning set forth in the first paragraph of this Agreement. 

1.40. “Supply Agreement” means that certain Supply Agreement, dated the Execution Date, between Sublicensor,
Actavis and Sublicensee. 
 1.41. “Term” has the meaning set forth in Section 5.1. 

1.42. “Territory” means the United States of America, its territories and possessions. 

1.43. “Third Party” means any Person other than the Parties and their respective Affiliates. 

1.44. “Third Party Claim” has the meaning set forth in Section 4.1. 

1.45. “Unlicensed Generic Product” means a Generic PEG Product that is sold in the Territory, other than the
Product or an Authorized Generic Product. 
  

	2.	Grant of Rights 

 2.1.
Sublicense. Subject to the terms and conditions of this Agreement, Sublicensor hereby grants to Sublicensee, effective as of the Start Date, a non-exclusive, non-

  
 7 

 
sublicensable (except to the extent contemplated by Section 2.3), fully paid up sublicense under Sublicensor’s rights in and to the Norgine Patents solely to make, have made, import,
use, sell, and offer for sale the Product in the Territory from and after the Start Date. 
 2.2. License. Subject
to the terms and conditions of this Agreement, Norgine hereby grants to Sublicensee, effective as of the Start Date, a non-exclusive, non-sublicensable (except to the extent contemplated by Section 2.3), fully paid up license under the Norgine
Patents solely to make, have made, import, use, sell, and offer for sale the Product in the Territory from and after the Start Date. 
 2.3. Sublicenses; Distributor. 
 (a) Sublicensee shall have the
right to sublicense its rights under Section 2.1 and 2.2 to its Majority-Controlled Affiliates, but any such sublicense may continue only for such period as the Majority-Controlled Affiliate receiving the sublicense shall continue as a
Majority-Controlled Affiliate. 
 (b) Sublicensor and Norgine each acknowledges and agrees that appointment by Sublicensee of
Actavis as a distributor of the Product in the Territory shall not constitute a sublicense of any rights sublicensed or licensed to Sublicensee pursuant to Sections 2.1 and 2.2. 

2.4. Waiver and Cooperation. 
 (a) Waiver. 
 (i) Sublicensor hereby agrees to waive and hereby waives, for
itself and its Affiliates, any and all regulatory exclusivities that may prevent marketing or sale of the Product within the scope of the sublicense granted in Section 2.1. 

(ii) Norgine hereby agrees to waive and hereby waives, for itself and its Affiliates, any and all regulatory exclusivities that may
prevent marketing or sale of the Product within the scope of the license granted in Section 2.2. 

  
 8 

  
 (b) Start of
Sublicense and License. The sublicense and license set forth in Sections 2.1 and 2.2, respectively, shall commence reasonably in advance of the Start Date solely for the purpose of permitting, and only to the extent necessary to permit,
Sublicensee and its Affiliates to make commercially reasonable preparations to sell Product as of the Start Date by (i) initiating manufacture of Product not more than [*] ([*]) days before the date on which the Start Date can be reasonably
anticipated by Sublicensee to occur and (ii) initiating offers for sale of Product not more than [*] ([*]) days before the date on which the Start Date can be reasonably anticipated by Sublicensee to occur. 

(c) Confirmation. 
 (i) As Sublicensee may reasonably request, Sublicensor shall confirm to the FDA the sublicenses and waivers granted by Sublicensor hereunder. 

(ii) As Sublicensee may reasonably request, Norgine shall confirm to the FDA the licenses and waivers granted by Sublicensor hereunder.

 (d) Notification. Sublicensor shall provide Sublicensee with notice as soon as practicable of both the expected, and
also of the actual, occurrence of the Start Date if other than September 24, 2018. Without limiting the foregoing, Sublicensor shall provide Sublicensee with not less than [*] ([*]) days’ prior notice of the date on which any commercial
scale quantities of an Authorized Generic Product are anticipated to be sold in the Territory. Notwithstanding anything in this Agreement to the contrary, Sublicensee may provide a copy of any notice received by it from Sublicensor pursuant to this
Section 2.4(d) to Actavis. 

  
 [*] Confidential treatment
requested; certain information omitted and filed separately with the SEC. 
 9 

  
 (e) No Challenges.

 (i) Sublicensor shall not, and shall cause its Affiliates not to, challenge or cause any Third Party to challenge
Sublicensee’s application to the FDA for approval of Product. 
 (ii) Norgine shall not, and shall cause its Affiliates
not to, challenge or cause any Third Party to challenge Sublicensee’s application to the FDA for approval of Product. 
  

	3.	Representations, Warranties and Covenants 

 3.1. Representations and Warranties of Each Party. Each Party hereby represents and warrants to the other Party as of the Execution Date as follows: 

(a) Such Party (i) is duly formed and in good standing under the laws of the jurisdiction of its formation, (ii) has the power
and authority and the legal right to enter into this Agreement and perform its obligations hereunder, and (iii) has taken all necessary action on its part required to authorize the execution and delivery of this Agreement and the performance of
its obligations hereunder. 
 (b) This Agreement has been duly executed and delivered on behalf of such Party and constitutes a
legal, valid and binding obligation of such Party and is enforceable against it in accordance with its terms, subject to the effects of bankruptcy, insolvency or other similar laws of general application affecting the enforcement of creditor rights
and judicial principles affecting the availability of specific performance and general principles of equity, whether enforceability is considered in a proceeding at law or equity. 

(c) All necessary consents, approvals and authorizations of all regulatory and governmental authorities and other Persons required to be
obtained by such Party in connection with the execution and delivery of this Agreement and the performance of its obligations hereunder have been obtained. 

  
 10 

  
 (d) The execution and
delivery of this Agreement and the performance of such Party’s obligations hereunder, (i) to the knowledge of such Party, do not and will not conflict with or violate any requirement of Applicable Law, (ii) do not and will not
conflict with or violate any provision of the articles of incorporation or bylaws of such Party, and (iii) do not and will not conflict with, violate, or breach, or constitute a default or require any consent under, any contractual obligation
or court or administrative order by which such Party is bound. 
 3.2. Representations and Warranties of
Sublicensor. Sublicensor hereby represents and warrants to Sublicensee as of the Execution Date that it is the exclusive licensee under the Norgine Patents to make, have made, use, have used, Commercialize and have Commercialized Product in the
Territory and, insofar as an agreements or other arrangements between Norgine and Sublicensor are concerned, has the right to grant the sublicenses set forth in Section 2.1. 

3.3. Representations and Warranties of Norgine. Norgine hereby represents and warrants to Sublicensee as of the Execution
Date that Sublicensor is the exclusive licensee under the Norgine Patents to make, have made, use, have used, Commercialize and have Commercialized Product in the Territory and, insofar as any agreements between Salix and Norgine are concerned, has
the right to grant the sublicenses set forth in Section 2.1. 
 3.4. DISCLAIMER OF WARRANTY. EXCEPT FOR THE
REPRESENTATIONS AND WARRANTIES SET FORTH HEREIN, NO PARTY MAKES ANY REPRESENTATIONS OR EXTENDS ANY WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF QUALITY, MERCHANTABILITY OR FITNESS FOR A PARTICULAR USE OR PURPOSE OR ANY WARRANTY AS TO
THE VALIDITY OF ANY PATENTS OR THE NON-INFRINGEMENT OF ANY INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES. 

  
 11 

  
 3.5.
Covenant Not to Sue. 
 (a) Covenant. 

(i) Sublicensor hereby covenants to Sublicensee that Sublicensor (and its Affiliates) shall not sue, and shall not aid, abet or enable
any Third Party in suing, the Sublicensee or, in its capacity as Sublicensee’s distributor, Actavis claiming that the manufacture, having manufactured, use, sale, offer for sale or importation of Product from and after the Start Date or the
commercially reasonable preparations to sell Product as of the Start Date as set forth in Section 2.4(b), in each case in or for the Territory, infringes any Norgine Patent. Sublicensor shall impose the foregoing covenant not to sue on any
Third Party to which it or any of its Affiliates may assign or otherwise transfer, or license or sublicense, any such patent rights. 
 (ii) Norgine hereby covenants to Sublicensee that Norgine (and its Affiliates) shall not sue, and shall not aid, abet or enable any Third Party in suing, the Sublicensee or, in its capacity as
Sublicensee’s distributor, Actavis claiming that the manufacture, having manufactured, use, sale, offer for sale or importation of Product from and after the Start Date or the commercially reasonable preparations to sell Product as of the Start
Date as set forth in Section 2.4(b), in each case in or for the Territory, infringes any Norgine Patent. Sublicensor shall impose the foregoing covenant not to sue on any Third Party to which it or any of its Affiliates may assign or otherwise
transfer, or license or sublicense, any such patent rights. 
 (b) Non-Exclusive License. For any Norgine Patent listed
now or in the future in the Orange Book for the Approved Product, the covenants not to sue set forth in Section 3.5(a) shall hereby be treated to also be in the form of a non-exclusive license so that Sublicensee and its Affiliates may continue
to maintain or file for such patents a 

  
 12 

 
“Paragraph IV Certification” under 21 U.S.C. § 355(j)(2)(A)(vii)(IV) (as amended or replaced). 

 

	4.	Indemnity; Limitation on Damages 

 4.1. Indemnification. In addition to any other remedy available to Sublicensor or Norgine, Sublicensee shall indemnify, defend and hold harmless each of Sublicensor, its Affiliates and its
and their respective officers, directors, partners, shareholders, employees and agents and Norgine, its Affiliates and its and their respective officers, directors, partners, shareholders, employees and agents (each, an “Indemnified
Party”) from and against any and all Losses incurred by them to the extent resulting from or arising out of or in connection with any claims made or suits brought by a Third Party (a “Third Party Claim”) that arise out of
or result from the manufacture, distribution, sales, marketing or use of Product pursuant to the sublicense and license granted hereunder. 
 4.2. Indemnification Procedure. 
 (a) An Indemnified Party shall
give Sublicensee prompt written notice (an “Indemnification Claim Notice”) of any Third Party Claim upon which such Indemnified Party intends to base a request for indemnification under Section 4.1, but in no event shall
Sublicensee be liable for any Losses that result from any delay in providing such notice. Each Indemnification Claim Notice must contain a description of the Third Party Claim and the nature and amount of the related Loss (to the extent that the
nature and amount of such Loss are known at such time). The Indemnified Party shall furnish promptly to Sublicensee copies of all papers and official documents received in respect of any Third Party Claim. 

(b) At its option, Sublicensee may assume the defense of any Third Party Claim by giving written notice to the Indemnified Party seeking
indemnification within thirty (30) days after Sublicensee’s receipt of an Indemnification Claim Notice for such 

  
 13 

 
Indemnified Party. The assumption of the defense of a Third Party Claim by Sublicensee shall constitute an acknowledgment that Sublicensee is liable to indemnify the Indemnified Party in respect
of the Third Party Claim. Upon assuming the defense of a Third Party Claim, Sublicensee may appoint as lead counsel in the defense of the Third Party Claim any legal counsel selected by Sublicensee that is reasonably acceptable to the Indemnified
Party. In the event Sublicensee assumes the defense of a Third Party Claim, the Indemnified Party shall promptly deliver to Sublicensee all original notices and documents (including court papers) received by the Indemnified Party in connection with
the Third Party Claim. Subject to Section 4.2(c), if Sublicensee assumes the defense of a Third Party Claim, Sublicensee shall not be liable to the Indemnified Party for any legal expenses subsequently incurred by such Indemnified Party in
connection with the analysis, defense or settlement of the Third Party Claim. 
 (c) Without limiting Section 4.2(b), the
Indemnified Party seeking indemnification shall be entitled to participate in, but not control, the defense of such Third Party Claim and to employ counsel of its choice for such purpose; provided, however, that such employment shall be at
the Indemnified Party’s own expense unless (i) the employment thereof at Sublicensee’s expense has been specifically authorized by Sublicensee in writing, (ii) Sublicensee has failed to assume the defense and employ counsel in
accordance with Section 4.2(b) (in which case the Indemnified Party shall control the defense), or (iii) the interests of the Indemnified Party and Sublicensee or any other Indemnified Party with respect to such Third Party Claim are
sufficiently adverse to prohibit the representation by a single counsel of Sublicensee and all relevant Indemnified Parties under Applicable Law, ethical rules or equitable principles. 

(d) With respect to any Losses relating solely to the payment of money damages in connection with a Third Party Claim and that will not
result in the Indemnified Party seeking indemnification becoming subject to injunctive or other relief or 

  
 14 

 
otherwise adversely affect the business of the Indemnified Party in any manner, and as to which Sublicensee shall have acknowledged in writing the obligation to indemnify the Indemnified Party
hereunder, Sublicensee shall have the sole right to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Losses, on such terms as Sublicensee, in its sole discretion, shall deem appropriate. With respect to
all other Losses in connection with Third Party Claims, where Sublicensee has assumed the defense of the Third Party Claim in accordance with Section 4.2(b), Sublicensee shall have authority to consent to the entry of any judgment, enter into
any settlement or otherwise dispose of such Loss; provided that it obtains the prior written consent of the Indemnified Party (which consent shall not be unreasonably withheld or delayed). If Sublicensee chooses to defend a Third Party Claim,
Sublicensee shall not be liable for any settlement or other disposition of any Losses by the Indemnified Party with respect to such Third Party Claim that is reached without the written consent of Sublicensee (which consent shall not be unreasonably
withheld or delayed). 
 (e) If Sublicensee chooses to defend any Third Party Claim, the Indemnified Party seeking
indemnification shall cooperate in the defense thereof and shall furnish such records, information and testimony, provide such witnesses and attend such conferences, discovery proceedings, hearings, trials and appeals as may be reasonably requested
in connection therewith. Such cooperation shall include access during normal business hours afforded to Sublicensee to, and reasonable retention by the Indemnified Party of, records and information that are reasonably relevant to such Third Party
Claim, and making employees and agents available on a mutually convenient basis to provide additional information and explanation of any material provided hereunder. Sublicensee shall reimburse the Indemnified Party for all its reasonable
out-of-pocket expenses in connection with activities contemplated by this Section 4.2(e). 

  
 15 

  
 (f) Except as
provided above, the reasonable and verifiable costs and expenses, including fees and disbursements of counsel, incurred by an Indemnified Party in connection with any Third Party Claim shall be reimbursed on a monthly basis in arrears by
Sublicensee. 
 4.3. LIMITATION ON DAMAGES. EXCEPT WITH RESPECT TO 

(a) A BREACH OF A PARTY’S OBLIGATIONS IN SECTION 6; and 

(b) ANY SALE OR OFFER FOR SALE OF THE PRODUCT IN THE TERRITORY PRIOR TO THE START DATE (OTHER THAN AS PERMITTED BY THIS AGREEMENT) NO
PARTY SHALL BE LIABLE FOR INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, EXEMPLARY OR PUNITIVE DAMAGES ARISING OUT OF THIS AGREEMENT OR THE EXERCISE OF ITS RIGHTS HEREUNDER OR FOR ANY LOSS OR INJURY TO A PARTY’S PROFITS OR GOODWILL ARISING FROM
OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF SUCH DAMAGES. NOTHING IN THIS SECTION 4.3 IS INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OF ANY INDEMNIFIED PARTY OR THE OBLIGATIONS OF SUBLICENSEE PURSUANT TO
SECTIONS 4.1 AND 4.2 WITH RESPECT TO THIRD PARTY CLAIMS. 
  

	5.	Term and Termination 

5.1. Term. The term of this Agreement shall commence on the Execution Date and, unless earlier terminated in accordance with
this Section 5, shall expire on the Expiration Date (the “Term”). 
 5.2. Termination for
Breach. This Agreement may be terminated by Sublicensor if Sublicensee shall be in breach of any material obligation hereunder and shall not have cured such breach within (a) [*] ([*]) days for breaches involving non-payment 

[*] Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  
 16 

  
 of amounts payable hereunder that are
not the subject of a good faith dispute or (b) [*] ([*]) days for all other breaches, in either case ((a) or (b)), after receipt of a written notice from Sublicensor requesting the cure of such breach. Such termination shall be effective upon
failure of Sublicensee to cure such breach within such period. 
 5.3. Termination for Bankruptcy. This Agreement
may be terminated by Sublicensor upon the filing or institution of any bankruptcy, reorganization, liquidation or receivership proceedings by Sublicensee, or upon the failure by Sublicensee for more than ninety (90) days to discharge any such
involuntary actions against it. Such termination shall be effective upon receipt of notice from Sublicensor. 
 5.4.
Certain Events. Upon the occurrence of a Settlement Termination Event (as such term is defined in the Settlement Agreement), this Agreement shall terminate. 
 5.5. Bankruptcy. All rights and licenses granted under or pursuant to this Agreement by Sublicensor and Norgine are, and shall otherwise be deemed to be, for purposes of Section 365(n)
of the U.S. Bankruptcy Code, licenses of right to “intellectual property” as defined under Section 101 of the U.S. Bankruptcy Code. The Parties agree that Sublicensee, as licensee of such rights under this Agreement, shall retain and
may fully exercise all of its rights and elections under the U.S. Bankruptcy Code. 
 5.6. Effect of Expiration or
Termination. Upon the expiration or earlier termination of this Agreement, (a) the licenses and rights granted by Sublicensor and Norgine under Section 2 shall terminate, (b) the covenants contained in, and the licenses and rights
granted by Sublicensor and Norgine under, Section 3.5 shall terminate, and (c) each Party, at the request of the other, shall return all data, files, records and other materials in its possession or control containing or comprising another
Party’s Confidential Information to the Disclosing Party, except the legal department of the Receiving Party may retain one copy solely for archival purposes. 
 [*] Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  
 17 

  
 5.7.
Assignment to Norgine. 
 (a) If the Head License is terminated in circumstances under which Sublicensor’s
rights thereunder are terminated, then this Agreement, and all of Sublicensor’s rights and remedies hereunder, shall automatically be assigned to Norgine, and hereby are assigned to Norgine, effective as of the date of such termination of the
Head License. Upon any assignment of this Agreement to Norgine pursuant to the preceding sentence, Norgine shall succeed to, and shall thereafter be bound by, Sublicensor’s duties and obligations hereunder (but not, for the avoidance of doubt,
any liabilities of Sublicensor arising before such time). 
 (b) In connection with any assignment effected pursuant to
Section 5.7(a), Sublicensor shall, upon Norgine’s written request, exercise its rights under Section 8.11(b) of the Supply Agreement to effect the assignment of its rights and remedies under the Supply Agreement to Norgine as
contemplated by, and subject to the conditions set forth in, Section 8.11(b) of the Supply Agreement. 
 5.8.
Survival. The expiration or earlier termination of this Agreement shall be without prejudice to any rights or obligations of the Parties that may have accrued prior to such expiration or termination, and the provisions of Sections 4, 5, 6
and 7 shall survive the expiration or termination of this Agreement. 
  

	6.	Confidentiality 

 6.1.
Confidential Information. Subject to the provisions of Sections 6.2 and 6.3, at all times during the Term and for five (5) years following the expiration or termination of this Agreement, the Receiving Party (a) shall keep
completely confidential and shall not publish or otherwise disclose any Confidential Information furnished to it by the Disclosing Party, except to those of the Receiving Party’s employees, Affiliates, or consultants who have a need to know
such information to perform such Party’s obligations or exercise such Party’s rights hereunder (and who shall be advised of the Receiving Party’s obligations hereunder and 

  
 18 

 
who are bound by confidentiality obligations with respect to such Confidential Information no less onerous than those set forth in this Agreement) (collectively, “Recipients”)
or, in respect of Confidential Information received by Sublicensee from Sublicensor, as otherwise permitted by Section 5.3(d) of the Supply Agreement and (b) shall not use Confidential Information of the Disclosing Party directly or
indirectly for any purpose other than performing its obligations or exercising its rights hereunder. 
 6.2.
Exceptions to Confidentiality. The Receiving Party’s obligations set forth in this Agreement shall not extend to any Confidential Information of the Disclosing Party: 

(a) that is or hereafter becomes part of the public domain by public use, publication, general knowledge or the like through no wrongful
act, fault or negligence on the part of a Receiving Party or its Recipients; 
 (b) that is received from a Third Party without
restriction and without breach of any agreement between such Third Party and the Disclosing Party; 
 (c) that the Receiving
Party can demonstrate by competent evidence was already in its possession without any limitation on use or disclosure prior to its receipt from the Disclosing Party; 
 (d) that is generally made available to Third Parties by the Disclosing Party without restriction on disclosure; or 
 (e) that the Receiving Party can demonstrate by competent evidence was independently developed by the Receiving Party. 
 6.3. Disclosure. A Party may disclose Confidential Information of another Party to the extent that such disclosure is: 

(a) made in response to a valid order of a court of competent jurisdiction or other governmental body of a country or any political
subdivision thereof of competent jurisdiction; provided, however, that the Receiving Party shall first have given 

  
 19 

 
notice to the Disclosing Party and given the Disclosing Party a reasonable opportunity to quash such order or to obtain a protective order requiring that the Confidential Information or documents
that are the subject of such order be held in confidence by such court or governmental body or, if disclosed, be used only for the purposes for which the order was issued; and provided further that if a disclosure order is not quashed or a
protective order is not obtained, the Confidential Information disclosed in response to such court or governmental order shall be limited to that information that is legally required to be disclosed in such response to such court or governmental
order; 
 (b) required or contemplated by Section 2.4(c) and (e); or 

(c) otherwise required by Applicable Law, in the opinion of counsel to the Receiving Party. 

6.4. Notification. The Receiving Party shall notify the Disclosing Party immediately, and cooperate with the Disclosing
Party as the Disclosing Party may reasonably request, upon the Receiving Party’s discovery of any loss or compromise of the Disclosing Party’s Confidential Information. 

6.5. Remedies. Each Party agrees that the unauthorized use or disclosure of any information by the Receiving Party in
violation of this Agreement will cause severe and irreparable damage to the Disclosing Party. In the event of any violation of this Section 6, the Receiving Party agrees that the Disclosing Party shall be authorized and entitled to obtain from
any court of competent jurisdiction injunctive relief, whether preliminary or permanent, without the necessity of proving irreparable harm or monetary damages, as well as any other relief permitted by applicable law. The Receiving Party agrees to
waive any requirement that the Disclosing Party post bond as a condition for obtaining any such relief. 
 6.6. Use of
Names. Except as otherwise expressly permitted under the Settlement Agreement or the Supply Agreement, no Party shall mention or otherwise use the name, insignia, symbol, trademark, trade name or logotype of another Party (or any

  
 20 

 
abbreviation or adaptation thereof) in any publication, press release, promotional material or other form of publicity without the prior written approval of such other Party in each instance. In
no event may Sublicensee use, register or seek to register any trademarks, trade dress or other indicia of origin that are owned or controlled by Sublicensor or its Affiliates or Norgine or its Affiliates. The restrictions imposed by this
Section 6.6 shall not prohibit any Party from making any disclosure identifying another Party that is required by Applicable Law; provided, however, that reasonable measures shall be taken to assure confidential treatment of such
information. 
 6.7. Press Releases. Except as expressly provided in Section 6.3, no Party shall make a press
release or other public announcement regarding this Agreement, the terms hereof or the transactions contemplated hereby without the prior written approval of the other Party. 

 

	7.	Miscellaneous 

 7.1.
Assignment. This Agreement shall be binding upon and shall inure to the benefit of each Party hereto, and each of its successors and permitted assigns. Except as otherwise provided herein, no Party shall have the power to assign or
otherwise transfer this Agreement or any interest herein or right hereunder without the prior written consent of the other Parties, and any such purported assignment, transfer or attempt to assign or transfer any interest herein or right hereunder
shall be void and of no effect. Notwithstanding the foregoing, any Party may, upon written notice to the other Parties but without obtaining the other Parties’ consent, assign its rights and obligations under this Agreement to any of its
Majority-Controlled Affiliates, to any lender providing financing to that Party or its Affiliates for collateral security purposes, or to any successor in interest to that Party’s entire business or, in the case of Sublicensor and Sublicensee,
to its Approved Product or Product business, respectively, provided that (a) notwithstanding any such assignment, such Party shall remain liable for its and its assignee’s performance under this Agreement; (b) no such
assignment 

  
 21 

 
shall in any manner limit or impair the obligations of that Party hereunder; and (c) following a transfer by a Party to its Majority-Controlled Affiliate, any subsequent transaction (other
than one that would result in the transfer of this Agreement back to the assigning Party) that would cause such Majority-Controlled Affiliate to cease to be a Majority-Controlled Affiliate of such Party shall be deemed to be an assignment of this
Agreement requiring consent hereunder. 
 7.2. Severability. To the fullest extent permitted by Applicable Law,
the Parties waive any provision of law that would render any provision in this Agreement invalid, illegal or unenforceable in any respect. If any provision of this Agreement is held to be invalid, illegal or unenforceable, in any respect, then such
provision will be given no effect by the Parties and shall not form part of this Agreement. To the fullest extent permitted by Applicable Law and if the rights or obligations of any Party will not be materially and adversely affected, all other
provisions of this Agreement shall remain in full force and effect and the Parties will use their best efforts to negotiate a provision in replacement of the provision held invalid, illegal or unenforceable that is consistent with Applicable Law and
achieves, as nearly as possible, the original intention of the Parties. 
 7.3. Governing Law. 

(a) This Agreement shall be governed and interpreted in accordance with the law of the State of New York, excluding any conflicts or
choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. 
 (b) Each Party irrevocably and unconditionally consents to the exclusive jurisdiction of the courts of general jurisdiction of the State of New York and the United States District Court for the Southern
District of New York sitting in the Borough of Manhattan (collectively, the “Courts”) for any action, suit or proceeding (other than appeals therefrom) concerning any matter arising out of or relating to this Agreement, and agrees
not 

  
 23 

 
to commence any action, suit or proceeding (other than appeals therefrom) related thereto except in such Courts. 
 (c) Each Party hereto further hereby irrevocably and unconditionally waives any objection to the laying of venue of any action, suit or proceeding (other than appeals therefrom) arising out of or relating
to this Agreement in the Courts and hereby further irrevocably and unconditionally agrees not to raise any objection at any time to the laying or maintaining of the venue of any such action, suit or proceeding in any of such Courts, irrevocably
waives any claim that such action, suit or other proceeding has been brought in an inconvenient forum and further irrevocably waives the right to object, with respect to such action, suit or other proceeding, that such Court does not have any
jurisdiction over such Party. 
 (d) Each Party hereto further agrees that, to the maximum extent permitted by Applicable Law,
service of any process, summons, notice or document by United States registered mail to its address and contact person for notices provided for in Section 7.4 shall be effective service of process for any action, suit or proceeding brought
against it under this Agreement in any of the Courts. 
 7.4. Notices. All notices, requests and other
communications hereunder must be in writing, specifically reference this Agreement in a prominent manner, and be delivered personally or by recognized international courier to the Parties at the following addresses: 

If to Sublicensor to: 
 Salix Pharmaceuticals, Inc. 
 1700 Perimeter Park Drive 

Morrisville, North Carolina 27560 
 Attention: Senior Vice President Business Development 

  
 23 

 with copies (which shall not constitute notice) to: 

Salix Pharmaceuticals, Inc. 
 1700 Perimeter Park Drive 
 Morrisville, North Carolina 27560 

Attention: General Counsel 
 and 
 Covington & Burling LLP 

1201 Pennsylvania Avenue, N.W. 
 Washington, D. C. 20004 
 Attention: Edward C. Britton, Esq. 

If to Norgine to: 
 If to Norgine B.V.: 
 Norgine B.V. 

Hogehilweg 7 

1101 CA Amsterdam ZO 
 The Netherlands 
 Attention: Managing Director 

If to Norgine Europe B.V. 
 Norgine Europe B.V. 
 Hogehilweg 7 

1101 CA Amsterdam ZO 
 The Netherlands 
 Attention: Managing Director 

In both cases with a copy to: 
 Norgine Limited 
 Norgine House 

Widewater Place 

Moorhall Road 

Harefield, Middlesex UB9 6NS 
 United Kingdom 
 Attention: General Counsel 

If to Sublicensee to: 
 Novel Laboratories, Inc. 
 400 Campus Drive 

Somerset, New Jersey 08873 
 Attention: President 

  
 24 

 with copies (which shall not constitute notice) to: 

Actavis Inc. 

60 Columbia Road, Bldg. B 
 Morristown, New Jersey 07960 
 Attention: Legal Department 

and 
 Leydig,
Voit & Mayer 
 Two Prudential Plaza 
 180 N. Stetson Avenue, Suite 4900 
 Chicago, IL 60601-6731 

Attention: Steven H. Sklar, Esq. 

All such notices, requests and other communications will (a) if delivered personally to the address as provided in this Section 7.4, be deemed
given upon receipt, and (b) if delivered by courier to the address as provided in this Section 7.4, be deemed given upon receipt. Any Party from time to time may change its address or other information for the purpose of notices to that
Party by giving notice specifying such change to the other Party hereto. 
 7.5. Relationship of the Parties. The
status of a Party under this Agreement shall be that of an independent contractor. Nothing contained in this Agreement shall be construed as creating a partnership, joint venture or agency relationship between the Parties or as granting any Party
the authority to bind or contract any obligation in the name of or on the account of the other Party or to make any statements, representations, warranties or commitments on behalf of the other Party. 

7.6. Entire Agreement; Amendment. This Agreement constitutes the entire agreement between the Parties with respect to the
subject matter hereof and supersedes all prior agreements, whether written or oral, with respect to the subject matter hereof. Each Party confirms that it is not relying on any representations or warranties of the other Party except as specifically
set forth herein. Any amendment or modification of this Agreement must be in writing and signed by authorized representatives of both Parties. 

  
 25 

 7.7. No Benefit to Third Parties. The representations, warranties,
covenants and agreements set forth in this Agreement are for the sole benefit of the Parties hereto and their successors and permitted assigns, and they shall not be construed as conferring any rights on any other Persons except as otherwise
expressly provided in Sections 4.1 and 4.2. 
 7.8. Waiver and Non-Exclusion of Remedies. Any term or
condition of this Agreement may be waived at any time by the Party that is entitled to the benefit thereof, but no such waiver shall be effective unless set forth in a written instrument duly executed by or on behalf of the Party waiving such term
or condition. No waiver by any Party of any term or condition of this Agreement, in any one or more instances, shall be deemed to be or construed as a waiver of the same or any other term or condition of this Agreement on any future occasion. The
rights and remedies provided herein are cumulative and do not exclude any other right or remedy provided by Applicable Law or otherwise available except as expressly set forth herein. 

7.9. Further Assurance. Each Party shall duly execute and deliver, or cause to be duly executed and delivered, such further
instruments and do and cause to be done such further acts and things, including the filing of such assignments, agreements, documents and instruments, as may be necessary or as the other Party may reasonably request in connection with this Agreement
or to carry out more effectively the provisions and purposes hereof, or to better assure and confirm unto such other Party its rights and remedies under this Agreement. 
 7.10. Construction. Except where the context requires otherwise, whenever used the singular includes the plural, the plural includes the singular, the use of any gender is applicable to all
genders and the word “or” has the inclusive meaning represented by the phrase “and/or”. Whenever this Agreement refers to a number of days, unless otherwise specified, such number refers to calendar days. The headings of this
Agreement are for convenience of reference only and do not define, describe, extend or limit the scope or intent 

  
 26 

 
of this Agreement or the scope or intent of any provision contained in this Agreement. The term “including” or “includes” as used in this Agreement means including, without
limiting the generality of any description preceding such term. The wording of this Agreement shall be deemed to be the wording mutually chosen by the Parties and no rule of strict construction shall be applied against any Party. 

7.11. Other Agreements. 
 (a) Simultaneously herewith, the Sublicensor and Sublicensee are entering into the Supply Agreement with Actavis and the Parties are entering into the Settlement Agreement with Actavis. The effectiveness
of this Agreement is explicitly conditioned on the simultaneous execution and delivery of the aforesaid Supply Agreement and Settlement Agreement by each of the parties thereto. 

(b) Sections 2 and 3.5 shall become effective only upon the occurrence of the Consent Judgment Entry Date, as such term is defined in
the Settlement Agreement. For the avoidance of ambiguity, in the event there is no Consent Judgment Entry Date, the provisions of Sections 2 and 3.5 shall never become effective. 

7.12. Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed an original
and all of which taken together shall be deemed to constitute one and the same instrument. An executed signature page of this Agreement delivered by facsimile transmission or by electronic mail in “portable document format”
(“.pdf”) shall be as effective as an original executed signature page. 
 [Signature page follows.] 

  
 27 

 IN WITNESS WHEREOF, the Parties have executed this Agreement on the Execution Date.

  

											
	Salix Pharmaceuticals, Inc.	  		  	Novel Laboratories, Inc.	  	
						
	By:	 	 /s/ Carolyn J. Logan
	  		  	By:	 	 /s/ Veerappan S. Subramanian
	  	
						
	Name:	 	 Carolyn J. Logan
	  		  	Name:	 	 Veerappan S. Subramanian
	  	
						
	Title:	 	 President and CEO
	  		  	Title:	 	 President and CEO
	  	
						
	Date:	 	 August 27, 2010
	  		  	Date:	 	 August 27, 2010
	  	
					
	Norgine B.V.	  		  		 		  	
						
	By:	 	 /s/ Frank P. Nooteboom
	  		  		 		  	
						
	Name:	 	 Frank P. Nooteboom
	  		  		 		  	
						
	Title:	 	 Director
	  		  		 		  	
						
	Date:	 	 August 27, 2010
	  		  		 		  	
					
	Norgine Europe B.V.	  		  		 		  	
						
	By:	 	 /s/ Peter Stein
	  		  		 		  	
						
	Name:	 	 Peter Stein
	  		  		 		  	
						
	Title:	 	 Director
	  		  		 		  	
						
	Date:	 	 August 27, 2010
	  		  		 		  	

 Signature Page to Sublicense AgreementSupply Agreement

  
 EXHIBIT 10.73

 Portions of this exhibit marked [*] are requested to be treated confidentially. 

EXECUTION VERSION 
 SUPPLY AGREEMENT 
 between 

SALIX PHARMACEUTICALS, INC. 
 and 
 ACTAVIS INC. 

and 

NOVEL LABORATORIES, INC. 
 Dated as of August 27, 2010 
 (Moviprep®) 

  
 TABLE OF CONTENTS 

 

							
	 ARTICLE I.    DEFINITIONS
	  	 	1	  
		
	 ARTICLE II.   MANUFACTURING AND SUPPLY
	  	 	8	  
	 2.1
	    	Qualification	  	 	8	  
	 2.2
	    	Purchase and Supply Obligations	  	 	9	  
	 2.3
	    	Forecasting, Order and Delivery of Product	  	 	10	  
	 2.4
	    	Materials	  	 	12	  
	 2.5
	    	Invoice and Payment	  	 	12	  
	 2.6
	    	Price	  	 	13	  
	 2.7
	    	Warranty	  	 	13	  
	 2.8
	    	Failure or Inability to Supply Product	  	 	14	  
	 2.9
	    	Additional Payments	  	 	16	  
	 2.10
	    	Current Capacity and Scale-Up Plans	  	 	16	  
	 2.11
	    	Costs and Expenses	  	 	18	  
	 2.12
	    	Amendment of Specifications	  	 	18	  
	 2.13
	    	Quality Agreement	  	 	19	  
	 2.14
	    	Quality Control Analyses and Release	  	 	19	  
	 2.15
	    	Maintenance of Facility	  	 	19	  
	 2.16
	    	Regulatory Cooperation of Actavis and Novel	  	 	20	  
	 2.17
	    	Inspection by Salix	  	 	20	  
	 2.18
	    	Notification of Regulatory Inspections; Communications	  	 	21	  
	 2.19
	    	Recalls and Withdrawals	  	 	21	  
	 2.20
	    	Compliance with Applicable Laws	  	 	22	  
	 2.21
	    	Retention of Manufacturing Records and Samples	  	 	22	  
	 2.22
	    	Exclusive Supply Arrangement	  	 	23	  
	 2.23
	    	Second Source	  	 	24	  
		
	 ARTICLE III.   INTELLECTUAL PROPERTY
	  	 	24	  
	 3.1
	    	Ownership of Inventions	  	 	24	  
	 3.2
	    	Prosecution of Invention Patents	  	 	25	  
	 3.3
	    	United States Law	  	 	25	  
	 3.4
	    	Corporate Names	  	 	25	  
		
	 ARTICLE IV.   REPRESENTATIONS AND WARRANTIES; COVENANTS
	  	 	26	  
	 4.1
	    	Representations and Warranties of Each Party	  	 	26	  
	 4.2
	    	Additional Warranties and Covenants of Actavis and Novel	  	 	26	  
	 4.3
	    	Disclaimer of Other Warranties	  	 	27	  
		
	 ARTICLE V.   CONFIDENTIALITY
	  	 	27	  
	 5.1
	    	Confidential Information	  	 	27	  
	 5.2
	    	Exceptions to Confidentiality	  	 	27	  

  
 -i-

  

							
	 5.3
	    	Disclosure	  	 	28	  
	 5.4
	    	Notification	  	 	29	  
	 5.5
	    	Remedies	  	 	29	  
	 5.6
	    	Use of Names	  	 	29	  
	 5.7
	    	Press Releases	  	 	29	  
		
	 ARTICLE VI.   TERM AND TERMINATION
	  	 	30	  
	 6.1
	    	Term	  	 	30	  
	 6.2
	    	Termination	  	 	30	  
	 6.3
	    	Effect of Expiration or Termination	  	 	32	  
	 6.4
	    	Bankruptcy of Actavis or Novel	  	 	33	  
		
	 ARTICLE VII.   INDEMNIFICATION
	  	 	36	  
	 7.1
	    	Novel Indemnification	  	 	36	  
	 7.2
	    	Salix Indemnification	  	 	36	  
	 7.3
	    	Actavis Indemnification	  	 	37	  
	 7.4
	    	Indemnification Procedure	  	 	37	  
	 7.5
	    	Insurance	  	 	39	  
	 7.6
	    	Limitation on Damages	  	 	40	  
		
	 ARTICLE VIII.   MISCELLANEOUS
	  	 	40	  
	 8.1
	    	Notices	  	 	40	  
	 8.2
	    	Force Majeure	  	 	41	  
	 8.3
	    	Entire Agreement; Amendment	  	 	42	  
	 8.4
	    	Further Assurances	  	 	43	  
	 8.5
	    	Successors and Assigns	  	 	43	  
	 8.6
	    	Dispute Resolution	  	 	43	  
	 8.7
	    	Governing Law; Jurisdiction; Venue; Service	  	 	43	  
	 8.8
	    	Audit; Late Payments	  	 	44	  
	 8.9
	    	Third Party Beneficiaries	  	 	45	  
	 8.10
	    	Export Control	  	 	45	  
	 8.11
	    	Assignment	  	 	45	  
	 8.12
	    	Waiver	  	 	46	  
	 8.13
	    	Severability	  	 	46	  
	 8.14
	    	Independent Contractors	  	 	47	  
	 8.15
	    	Construction	  	 	47	  
	 8.16
	    	Remedies	  	 	47	  
	 8.17
	    	Counterparts; Facsimile Execution	  	 	47	  
	 8.18
	    	English Language	  	 	47	  
	 8.19
	    	Other Agreements	  	 	48	  

 Schedules and Exhibits

  

			
	Schedule 1.52	  	Product Active Ingredients

  
 -ii-

  

			
	Schedule 1.54	 	Product Patents
	Schedule 1.68	 	Specifications
	Schedule 2.3(a)	 	Non-Binding Estimate of Requirements for Calendar Year 2011
	Schedule 2.3(c)	 	Full Production Lot Sizes
	Schedule 2.10(a)	 	Current Capacity
	Schedule 2.10(e)	 	Anticipated Equipment Needs

  
 -iii-

  
 This SUPPLY
AGREEMENT (this “Agreement”), dated as of August 27, 2010 (the “Effective Date”), is made by and between Salix Pharmaceuticals, Inc., a California corporation (“Salix”), Actavis Inc., a
Delaware corporation (“Actavis”), and Novel Laboratories, Inc., a Delaware corporation (“Novel”). Salix, Actavis and Novel are sometimes referred to herein individually as a “Party” and collectively
as the “Parties.” 
 RECITALS 
 WHEREAS, subject to the terms and conditions set forth in this Agreement, Salix wishes to have Actavis supply Product (as defined below) manufactured by Novel, Actavis’s contract manufacturer,
Novel wishes to manufacture Product for Actavis, and Actavis wishes to supply Product to Salix; and 
 WHEREAS, the
Parties, Norgine B.V. and Norgine Europe B.V. (collectively, “Norgine”) are entering into a Settlement Agreement, of even date herewith (the “Settlement Agreement”); and 

WHEREAS, the Parties are entering into a Sublicense Agreement, of even date herewith (the “Sublicense
Agreement”); 
 NOW, THEREFORE, in consideration of the foregoing premises, the mutual promises and covenants of
the Parties contained herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, do hereby agree as follows: 

ARTICLE I. DEFINITIONS 
 As used herein, the following terms shall have the following meanings: 
 1.1
“Acknowledgement” has the meaning set forth in Section 2.3. 
 1.2 “Actavis” has the
meaning set forth in the preamble hereto. 
 1.3 “Actavis and Novel Indemnified Parties” has the meaning set
forth in Section 7.2. 
 1.4 “Affiliate” of a Person means any other Person that directly, or indirectly
through one or more intermediaries, controls, is controlled by or is under common control with, such first Person. “Control” and, with correlative meanings, the terms “controlled by” and “under common
control with”, means to possess the power to direct the management or policies of a Person, whether through ownership of voting securities or by contract or otherwise. 

1.5 “Agreement” has the meaning set forth in the preamble hereto. 

  
 1.6
“Applicable Law” means applicable laws, rules and regulations, including any rules, regulations, guidelines or other requirements of the Regulatory Authorities, that may be in effect from time to time. 

1.7 “Business Day” means a day other than a Saturday or a Sunday on which banks in general in New York, New York are
open for the conduct of normal commercial banking business at their counters. 
 1.8 “Calendar Year” means each
successive period of twelve (12) consecutive calendar months commencing on January 1 and ending on December 31, except that the first Calendar Year of the Term shall commence on the Effective Date and end on December 31, 2010,
and the last Calendar Year of the Term shall commence on January 1 of the year in which the Term ends and end on the last day of the Term. 
 1.9 “Capacity” means the capacity of Novel’s plant, equipment and process to conduct the Manufacturing process and to supply Product to Actavis for supply to Salix in accordance with
the terms hereof. 
 1.10 “Certificate of Analysis” has the meaning set forth in the Quality Agreement.

 1.11 “Certificate of Compliance” has the meaning set forth in the Quality Agreement. 

1.12 “CMC Data” means the chemistry, manufacturing and controls data required by Applicable Law to be included in a New
Drug Application (as defined in the FFDCA and the regulations promulgated thereunder) for Product in the Territory. 
 1.13
“Confidential Information” means any and all information or material that, at any time before or after the Effective Date, has been or is provided or communicated to the Receiving Party by or on behalf of the Disclosing Party
(including by a third party) pursuant to this Agreement or in connection with the transactions contemplated hereby or any discussions or negotiations with respect thereto; any data, ideas, concepts or techniques contained therein; and any
modifications thereof or derivations therefrom. Confidential Information may be disclosed either orally, visually, electronically, in writing, by delivery of materials containing Confidential Information or in any other form now known or hereafter
invented. 
 1.14 “Consent Judgment Entry Date” has the meaning set forth in the Settlement Agreement.

 1.15 “Corporate Names” means such Trademarks and corporate names and logos owned or controlled by Actavis or
Novel or their Affiliates as Actavis or Novel, respectively, may designate in writing from time to time, together with any variations and derivatives thereof. 

  
 -2-

  
 1.16
“Courts” has the meaning set forth in Section 8.7(b). 
 1.17 “Covered Product” means the
Product and any other pharmaceutical product Covered by United States patent no. 7,169,381. For purposes of this definition, “Covered” in respect of a product means where a claim in a specified patent would be infringed by the
making, having made, offering for sale, selling or importation of the product in the United States in the absence of a valid license or other authorization. 
 1.18 “Current Capacity” has the meaning set forth in Section 2.10(a). 
 1.19 “Data Exclusivity” has the meaning set forth in Section 1.47. 
 1.20 “Disclosing Party” means the Party disclosing Confidential Information. 
 1.21 “Dispute” has the meaning set forth in Section 8.6. 

1.22 “Effective Date” has the meaning set forth in the preamble hereto. 

1.23 “Excluded Lists” means the Department of Health and Human Service’s List of Excluded Individuals/Entities and
the General Services Administration‘s Lists of Parties Excluded from Federal Procurement and Non-Procurement Programs. 

1.24 “Exploit” means to make, have made, import, use, sell, offer for sale or otherwise dispose of a compound, product
or process, including all discovery, research, development, commercialization, registration, modification, enhancement, improvement, Manufacture, storage, formulation, optimization, exportation, transportation, distribution, promotion and marketing
of such compound, product or process. 
 1.25 “Facility” means the Manufacturing facility of Novel located at
400 Campus Drive, Somerset, New Jersey 08873. 
 1.26 “FDA” means the United States Food and Drug
Administration and any successor agency thereto. 
 1.27 “FFDCA” has the meaning set forth in Section 2.7.

 1.28 “Firm Forecast” has the meaning set forth in Section 2.3(b). 

1.29 “Forecast” has the meaning set forth in Section 2.3(b). 

1.30 “GMP” means the current good manufacturing practices applicable from time to time to the Manufacturing of Product
pursuant to Applicable Law. 
 1.31 “Head License” means the License and Supply Agreement, dated
December 7, 2005, as amended, between Norgine and Salix. 

  
 -3-

  
 1.32
“Indemnification Claim Notice” has the meaning set forth in Section 7.4(a). 
 1.33 “Indemnified
Party” has the meaning set forth in Section 7.4(a). 
 1.34 “Indemnifying Party” has the meaning
set forth in Section 7.4(a). 
 1.35 “Informational Forecast” has the meaning set forth in
Section 2.3(a). 
 1.36 “Invention” means any discovery, improvement, process, formula, data, invention,
know-how, trade secret, procedure, device, or other intellectual property, whether or not patentable, including any enhancement in the manufacture, formulation, ingredients, preparation, presentation, means of delivery, dosage or packaging of a
compound or product or any discovery or development of a new indication for a compound or product. 
 1.37 “Invention
Patent” has the meaning set forth in Section 3.2. 
 1.38 “Joint Invention” means any Invention
that is conceived, discovered, developed or otherwise made jointly by or on behalf of Salix, on the one hand, or on behalf of Actavis or Novel or both of them, on the other hand, as a result of or in connection with this Agreement. 

1.39 “Losses” has the meaning set forth in Section 7.1. 

1.40 “Majority-Controlled Affiliate” (a) means, with respect to a Person, any Person that owns, directly or
indirectly, more than fifty percent (50%) of the outstanding voting securities, or other voting ownership interest, of such Person; any Person of which the first Person owns, directly or indirectly, more than fifty percent (50%) of the
outstanding voting securities, or other voting ownership interest, of such Person; or any Person of which a Person owning, directly or indirectly, more than fifty percent (50%) of the outstanding voting securities, or other voting ownership
interest, of the first Person owns, directly or indirectly, more than fifty percent (50%) of the outstanding voting securities, or other voting ownership interest, of such Person; and, (b) with respect to Novel, includes GAVIS
Pharmaceuticals, LLC. 
 1.41 “Manufacture” and “Manufacturing” means the manufacturing,
processing, formulating, packaging, labeling, holding and quality control testing of Product pursuant to Salix’s Marketing Authorization for the Product. 
 1.42 “Marketing Authorization” means an approved New Drug Application as defined in the FFDCA and the regulations promulgated thereunder, or any corresponding foreign application,
registration or certification, necessary or reasonably useful to market Product in a country or regulatory jurisdiction in the Territory other than the United States, including applicable pricing and reimbursement approvals. 

  
 -4-

  
 1.43
“Material(s)” means all ingredients, raw materials, packaging and labeling components, and all other supplies of any kind, required or used in connection with the Manufacturing of Product or any component or intermediate thereof.

 1.44 “Norgine” has the meaning set forth in the recitals hereto. 

1.45 “Novel” has the meaning set forth in the preamble hereto. 

1.46 “Party” and “Parties” has the meaning set forth in the preamble hereto. 

1.47 “Patents” means (a) all national, regional and international patents and patent applications, including
provisional patent applications, (b) all patent applications filed either from such patents, patent applications or provisional applications or from an application claiming priority from either of these, including divisionals, continuations,
continuations-in-part (other than with respect to new subject matter that would not otherwise be covered in this Agreement), provisionals, converted provisionals and continued prosecution applications, (c) any and all patents that have issued
or in the future issue from the foregoing patent applications ((a) and (b)), including utility models, petty patents and design patents and certificates of invention, (d) any and all extensions or restorations by existing or future extension or
restoration mechanisms, including revalidations, reissues, re-examinations and extensions (including any supplementary protection certificates and the like) of the foregoing patents or patent applications ((a), (b) and (c)), (e) any
similar rights, including so-called pipeline protection or any importation, revalidation, confirmation or introduction patent or registration patent or patent of additions to any of such foregoing patent applications and patents ((a), (b),
(c) and (d)), and (f) any data or market exclusion periods, including any such periods listed in the FDA’s Orange Book and all international equivalents (“Data Exclusivity”). 

1.48 “Person” means an individual, sole proprietorship, partnership, limited partnership, limited liability partnership,
corporation, limited liability company, business trust, joint stock company, trust, unincorporated association, joint venture or other similar entity or organization, including a government or political subdivision, department or agency of a
government. 
 1.49 “Per-Unit Supply Price” means the price paid by Salix to Actavis in respect of a particular
Unit of Product pursuant to the provisions of Section 2.6. 
 1.50 “Policies” has the meaning set forth in
Section 7.5(a). 
 1.51 “PPI” means the United States Producer Price Index for pharmaceutical
preparations, as compiled and published by the Bureau of Labor Statistics of the United States Department of Labor and using the latest version of data published as of the date of adjustment. 

  
 -5-

  
 1.52
“Product” means the pharmaceutical product described in New Drug Application No. 21-881 as filed with the FDA by Norgine but now owned by Salix, the active ingredients in which pharmaceutical product are set out in Schedule
1.52. 
 1.53 “Product Inventions” has the meaning set forth in Section 3.1. 

1.54 “Product Patents” means the Patents set forth on Schedule 1.54. 

1.55 “Purchase Order” means a written purchase order that sets forth, with respect to the period covered thereby,
(a) the quantities of Product to be delivered by Novel, on behalf of Actavis, to Salix and (b) the required delivery dates therefor. 
 1.56 “Qualification” means all activities required or associated with obtaining Regulatory Approval for Novel to Manufacture Product in accordance with Applicable Law and Salix’s
Marketing Authorization for the Product. 
 1.57 “Qualification Date” has the meaning set forth in
Section 2.1. 
 1.58 “Quality Agreement” means the quality assurance agreement to be agreed between the
Parties relating to the Manufacture of Product in accordance with Section 2.13, as such agreement shall be amended from time to time. 
 1.59 “Receiving Party” means the Party receiving Confidential Information. 
 1.60 “Recipients” has the meaning set forth in Section 5.1. 

1.61 “Regulatory Approval” means, with respect to any particular country or other jurisdiction, any and all approvals,
licenses, registrations or authorizations of any Regulatory Authority necessary for the Exploitation of Product in such country or jurisdiction, including, where applicable, (a) approval of Product in such country or jurisdiction, including any
Marketing Authorization and supplements and amendments thereto; (b) pre- and post-approval marketing authorizations (including any prerequisite Manufacturing approval or authorization related thereto); (c) labeling approval; and
(d) technical, medical and scientific licenses. 
 1.62 “Regulatory Authority” means any applicable
supra-national, federal, national, regional, state, provincial or local regulatory agencies, departments, bureaus, commissions, councils or other government entities regulating or otherwise exercising authority with respect to the Exploitation of
Product in any country or other jurisdiction. 
 1.63 “Salix” has the meaning set forth in the preamble hereto.

 1.64 “Salix and Actavis Indemnified Parties” has the meaning set forth in Section 7.1. 

  
 -6-

  
 1.65 “Salix
and Novel Indemnified Parties” has the meaning set forth in Section 7.3. 
 1.66 “Scale-Up Plans”
has the meaning set forth in Section 2.10(c). 
 1.67 “Settlement Agreement” has the meaning set forth in
the preamble. 
 1.68 “Specifications” means the specifications for Product and Materials set forth on
Schedule 1.68, as the same may be amended from time to time in accordance with the terms hereof. 
 1.69 “Start
Date” has the meaning set forth in the Sublicense Agreement. 
 1.70 “Sublicense Agreement” has the
meaning set forth in the preamble. 
 1.71 “Supply Term Commencement Date” means [*] 2011. 

1.72 “Term” has the meaning set forth in Section 6.1. 

1.73 “Territory” means the United States. 
 1.74 “Testing Laboratory” has the meaning set forth in Section 2.8(d). 
 1.75 “Third Party Claim” has the meaning set forth in Section 7.4(b). 
 1.76 “Trademark” shall include any word, name, symbol, color, designation or device or any combination thereof, including any trademark, trade dress, brand mark, service mark, trade name,
brand name, logo or business symbol, whether or not registered. 
 1.77 “Unit” means a single kit containing a
one (1) liter Moviprep container, two (2) Pouch A’s, and two Pouch B’s, each such kit constituting a complete single adult purgative preparation. 
 1.78 “United States” means the United States of America, its territories and possessions (including Puerto Rico). 
 1.79 “Valid Claim” means (a) any claim of an issued and unexpired Patent in the Territory that (i) has not been held permanently revoked, unenforceable or invalid by a decision
of a court or governmental agency of competent jurisdiction, which decision is unappealable or unappealed within the time allowed for appeal and (ii) has not been abandoned, disclaimed, denied or admitted to be invalid or unenforceable through
reissue or disclaimer or otherwise; or (b) a claim of a pending Patent application in the Territory that was filed and is being prosecuted in good faith and has not been abandoned or finally disallowed without the possibility of appeal or
re-filing of the application; provided that such prosecution has not been ongoing for more than six (6) years. 
  

[*] Confidential Treatment requested; certain information omitted and filed separately with the SEC. 

  
 -7-

  
 ARTICLE II.
MANUFACTURING AND SUPPLY 
 2.1 Qualification. 

(a) Actavis, Novel and Salix agree to use their commercially reasonable efforts to effect the qualification of Novel to Manufacture
Product, and of Actavis to supply Product Manufactured by Novel, by [*], including by (i) undertaking such quality and manufacturing systems reviews and audits of the Facility and Novel’s other operations as are necessary or advisable in
order to prepare for Novel’s qualification, (ii) making all such filings and taking all such other actions as are necessary or advisable to the obtaining of all Regulatory Approvals necessary for Novel to Manufacture Product, and for
Actavis to supply Product Manufactured by Novel, hereunder, and (iii) causing Norgine to timely assist in this respect by providing Novel the necessary technology transfer, data, information and other technical assistance reasonably required by
Novel to become qualified to Manufacture Product to be supplied hereunder. In any event, and without limitation of the terms of the preceding sentence, Salix, Actavis and Novel shall at all times following the Effective Date cooperate and act in
good faith to effect the qualification of Novel to Manufacture Product, and Actavis to supply Product Manufactured by Novel, as soon as is practicable after the Effective Date, including through an initial regulatory submission with appropriate
stability data as determined by Salix. The date upon which Novel's qualification to Manufacture Product, and Actavis's qualification to supply Product Manufactured by Novel, is effected as contemplated by this Section 2.1(a) shall be referenced
herein as the “Qualification Date”. Prior to submission to FDA, Actavis and Novel shall have the right to review and comment upon Salix's proposed regulatory submission to FDA to obtain the Regulatory Approvals necessary to effect
the qualification of Novel as a supplier of Product, and Salix shall appropriately consider Actavis's and Novel’s comments when finalizing its regulatory submission. For clarity, Salix shall have final authority to determine the contents of any
and all such regulatory submissions. 
 (b)In the event that the Supply Term Commencement Date precedes the Qualification Date,
then during the period between the Supply Term Commencement Date and the Qualification Date, Salix shall on a monthly basis pay to Actavis [*]. Such payments shall be made on or before the last day of each month during the period between the Supply
Term Commencement Date and the Qualification Date. For the avoidance of ambiguity, the Parties acknowledge and agree that no minimum purchase and supply obligation applies to Calendar Years subsequent to Calendar Year 2012 and that, accordingly, the
obligations set forth in the preceding sentence shall apply only in respect of periods through the end of Calendar Year 2012. The number of Units required to be purchased by Salix and supplied by Actavis for purposes of this Section 2.1(b) in
any given month shall be determined by taking the [*] of Units required to be purchased by Salix and supplied by Actavis pursuant to Section 2.2(b) (without reduction pursuant to Section 2.1(c)) during the Calendar Year in which such month
falls and dividing such 
  
 [*] Confidential Treatment requested;
certain information omitted and filed separately with the SEC. 

  
 -8-

 
number by twelve (12). In the event that Salix should make payment for Units pursuant to this Section 2.1(b), then Salix shall be entitled following the Qualification Date to obtain, after
it has purchased from Actavis, or made payment to Actavis pursuant to this Section 2.1(b) for, the [*] of Units required to be purchased by Salix and supplied by Actavis in respect of the current Calendar Year (the [*] required purchases in
respect of a partial Calendar Year to be determined in the manner set out in the preceding sentence) pursuant to Section 2.2(b), up to that number of Units for which it has made payment under this Section 2.1(b) without further payment to
Actavis therefor. Any Units to be obtained by Salix pursuant to the preceding sentence shall be subject to the ordering and forecasting requirements otherwise applicable under this Article II. 

(c) Notwithstanding anything to the contrary herein, in the event that the Supply Term Commencement Date precedes the Qualification Date,
then, subject only to the provisions of Section 2.1(b), the purchase and supply obligations set out in Section 2.2 and the forecasting and ordering requirements set out in Section 2.3 shall be suspended until the Qualification Date
and reduced pro rata as appropriate in order to take account of any partial Calendar Years comprising the period of time between the Supply Term Commencement Date and the Qualification Date. 

2.2 Purchase and Supply Obligations. 
 (a) Any purchase of Product by Salix from Actavis, and supply of Product by Actavis to Salix, during Calendar Year 2010 shall be made only pursuant to mutual agreement of Salix, Actavis and Novel as to
quantities of Product to be so purchased and supplied. 
 (b) Subject to Sections 2.2(c) and 2.8, Salix shall order from Actavis
Product in accordance with the following: 
 (i) [*] of Salix’s requirements of the Product in excess of [*] Units ordered
for delivery during the 2011 Calendar Year, and in any event not less than [*] Units ordered for delivery during the 2011 Calendar Year; 
 (ii) [*] of Salix’s requirements of the Product ordered for delivery during the 2012 Calendar Year, and in any event not less than [*] Units ordered for delivery during the 2012 Calendar Year; and

 (iii) [*] of Salix’s requirements of the Product ordered for delivery during the 2013 Calendar Year and in each
Calendar Year thereafter. 
 (c) In the event Salix should purchase any Product from Actavis ordered for delivery during
Calendar Year 2010, then Salix shall be entitled to credit the number of Units so purchased by it against its minimum purchase obligations set forth in 2.2(b) for Calendar Year 2011 and subsequent Calendar Years until exhausted. For the 

 
 [*] Confidential Treatment requested; certain information omitted and filed
separately with the SEC. 

  
 -9-

 
avoidance of doubt, Salix purchases ordered for delivery in excess of the minimum for the 2011 Calendar Year shall not be creditable against the minimum purchase obligation for the 2012 Calendar
Year. 
 (d) For each Calendar Year in which Salix is required pursuant to Section 2.2(b) to order all or a specific
portion of its requirements of Product from Actavis, Salix shall provide, within thirty (30) days after the end of that Calendar Year, a certification that it has ordered all or such specific portion, as the case may be, of its requirements of
Product for that Calendar Year from Actavis. Actavis shall have the right to audit Salix's financial records, pursuant to and in accordance with Section 8.8, to confirm that Salix has, from time to time, ordered such requirements pursuant to
Section 2.2(b). 
 (e) The Parties acknowledge and agree that the provisions of this Agreement relating to manufacturing
and supply of Product are not intended to apply in respect of any rights to Exploit Product outside of the Territory and that manufacturing and supply arrangements that may apply to any such rights that may be granted to or acquired by Salix will be
governed by a separate supply agreement, any such separate supply agreement to be entirely at the discretion of Novel and Salix, provided such agreement does not adversely affect Novel’s ability to supply Product for the Territory, and orders
for Product in the Territory are given priority over any such other orders. 
 (f) In the event that Salix desires to obtain
supply of any pharmaceutical product (other than the Product) that constitutes a Covered Product in respect of rights to Exploit Product in the Territory, Actavis and Novel, acting together, shall have the option to act as Salix's sole supplier for
such product on terms substantially the same as those set forth in this Agreement. Actavis and Novel shall exercise such option by notice to Salix given within thirty (30) days following notice given by Salix to Actavis and Novel of its desire
to obtain supply of a pharmaceutical product (other than the Product) that constitutes a Covered Product and providing information in reasonable detail regarding the nature of the contemplated Covered Product, anticipated quantities, timing
considerations and other such matters as are reasonably necessary in order to permit Actavis and Novel to make an informed evaluation of the opportunity. In the event that Actavis and Novel should fail to exercise their option in a timely manner and
otherwise as contemplated by the preceding sentence, the option shall terminate and be of no further force and effect in respect of the Covered Product described by Salix in its notice to Actavis and Novel. 

2.3 Forecasting, Order and Delivery of Product. 
 (a) Schedule 2.3(a) sets forth Salix’s good faith estimate of its Product purchase requirements for Calendar Year 2011. The Parties agree and acknowledge that such estimate shall be
non-binding and shall be used by Actavis and Novel for planning purposes only. Within ten (10) days following the Consent Judgment Entry Date, the 
  

  

 
Parties shall meet and discuss the quantities of Product that Salix expects to purchase from Actavis during Calendar Year 2011. At least [*] ([*]) days prior to the first day of each subsequent
Calendar Year during the Term, Salix shall deliver to Actavis and Novel a written good faith forecast estimating, on a quarterly basis, the quantities of Product that Salix expects to purchase from Actavis during such Calendar Year (each, an
“Informational Forecast”). Each Informational Forecast shall be non-binding and shall be used for planning purposes only. 
 (b) Commencing with a month that is at least [*] ([*]) month prior to the Supply Term Commencement Date, on the fifteenth (15th) day of each month (or, at Salix's discretion, at any time from the eighth (8th) day of such month up to and including the twenty-second
(22nd) day of such month), Salix shall deliver to
Actavis and Novel a written good faith forecast estimating the quantities of Product that Salix expects to purchase from Actavis for each month during the following twelve (12) months (each, a “Forecast”). The first [*] ([*])
months of each Forecast shall be a “Firm Forecast”. Except as provided in clause (c) below, each Forecast shall be non-binding and shall be used for planning purposes only. 

(c) Without duplication of any previously delivered Purchase Order, each Firm Forecast shall be accompanied by a Purchase Order for
Product to be delivered to Salix during each of the first [*] ([*]) months, respectively, set forth in such Firm Forecast. The quantity of Product specified in any Purchase Order for delivery in any month (i) shall be in multiples of the full
production lots of Product set forth on Schedule 2.3(c), (ii) shall not be more than [*] percent ([*]%) of the quantities specified in the most recent Firm Forecast applicable to such month, without Novel's consent, and (iii) shall,
unless otherwise agreed by Novel in writing, be consistent with Novel’s Current Capacity (or any increased capacity available to Novel as of the Supply Term Commencement Date (or, if later, the Qualification Date) or as subsequently agreed
pursuant to a Scale-Up Plan). 
 (d)With respect to each Purchase Order, Salix shall be obligated to purchase, and Actavis and
Novel shall be obligated to deliver, by the required delivery date and in the form set forth therein such quantities of Product as are set forth therein. The requested delivery date for Product shall not be less than [*] ([*]) days after the
Purchase Order is placed. Within [*] ([*]) Business Days following receipt of a Purchase Order, Actavis shall send a written acknowledgment (“Acknowledgment”) of its acceptance or rejection of such Purchase Order, in whole or in
part; provided, however, that, if no Acknowledgment is sent by Actavis within [*] ([*]) Business Days following receipt of a Purchase Order, the Purchase Order shall be deemed to be accepted. The Acknowledgement shall either confirm
the delivery date set forth in the Purchase Order or set forth a reasonable alternative delivery date, which shall not, without Salix’s prior written consent, be later than [*] ([*]) Business Days following the delivery date set forth in the
Purchase Order. In the event that the terms of any Purchase Order are not consistent with or are in addition to the terms of this Agreement, the terms of this 
  

[*] Confidential Treatment requested; certain information omitted and filed separately with the SEC. 

  
 -11-

 
Agreement shall prevail. Notwithstanding anything in this Section 2.3(d), Actavis and Novel shall use commercially reasonable efforts to commit to delivery on the delivery date set forth in
each Purchase Order. 
 (e) Actavis and Novel shall deliver the quantities of Product set forth in each Purchase Order to Salix
by the required delivery date set forth in the related Acknowledgement (or Purchase Order, if no Acknowledgement is sent) EXW the Facility (Incoterms 2000). All Product shall be labeled in accordance with Applicable Law and packed for shipping in
accordance with packing instructions provided by Salix. Title to and risk of loss of Product shall pass to Salix at the time of delivery. 
 (f) Each delivery of Product shall be accompanied by (i) a Certificate of Analysis, (ii) a Certificate of Compliance, (iii) such other documents as may be required pursuant to the Quality
Agreement, and (iv) such other documents as may be necessary for the sale of the Product. 
 2.4 Materials.

 (a) Novel shall maintain an inventory of Materials in sufficient quantities and shall use commercially reasonable efforts to
supply Salix with quantities of Product that are up to [*] percent ([*]%) of the quantities specified in each Firm Forecast. For the avoidance of doubt, Salix shall not be required to supply any Materials. 

(b) Novel shall be responsible for auditing and qualifying its supplier(s) of Materials and obtaining supplies of Materials in accordance
with the Specifications. All Materials shall conform to the applicable Specifications. 
 2.5 Invoice and Payment.

 (a) Actavis promptly shall invoice Salix for all quantities of Product delivered in accordance herewith. Payment with respect
to Product delivered shall be due thirty (30) days after receipt by Salix of the invoice with respect thereto; provided that if Salix rejects such Product pursuant to Section 2.8, then payment shall be due within thirty
(30) days after receipt by Salix of notice from the Testing Laboratory that the invoiced Product is conforming or, subject to Section 2.8, receipt by Salix of replacement Product, as the case may be; provided further, that if Salix
disputes any portion of an invoice, it shall pay the undisputed portion and shall provide Actavis with written notice of the disputed portion and its reasons therefor, and Salix shall not be obligated to pay such disputed portion. Actavis and Salix
shall use good faith efforts to resolve any such disputes promptly. In the event of any inconsistency between an invoice and this Agreement, the terms of this Agreement shall control. Payment of invoices shall be made by wire transfer to an account
designated in writing by Actavis in United States Dollars. 
 (b) Except as provided in Sections 2.9, 2.10(e), 2.12(d) and
6.3(d), Actavis shall be responsible for making any and all payments to Novel in respect of 
  
 [*] Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  
 -12-

 
Manufacture and delivery of the Product hereunder. Except as provided in Sections 2.9, 2.10(e), 2.12(d) and 6.3(d), Salix shall have no obligation whatsoever to make any payment to Novel in
respect of the Manufacture and delivery of Product hereunder. 
 2.6 Price. The Per-Unit Supply Price for all Product to
be supplied hereunder shall be as follows: 
 (a) for all orders of Product ordered for delivery in [*], [*] United States
Dollars ($[*]); 
 (b) for all orders of Product ordered for delivery in [*], [*] United States Dollars ($[*]); 

(c) for all orders of Product ordered for delivery in [*], [*] United States Dollars ($[*]); 

(d) for all orders of Product ordered for delivery in [*], [*] United States Dollars ($[*]); 

(e) for all orders of Product ordered for delivery in [*], [*] United States Dollars ($[*]); and 

(f) for all orders of Product ordered for delivery in [*] and in each subsequent [*], an amount equal to the [*] increased by an amount
equal to [*], provided that the amount of such an increase in respect of any [*] shall not exceed [*] percent ([*]%). 
 2.7
Warranty. 
 (a) In connection with each delivery of Product to Salix hereunder, Novel hereby represents and warrants to
Actavis and Salix as of the time of the delivery of such Product to Salix as follows: (a) such Product is in conformity with the Specifications and the Certificate of Analysis therefor provided pursuant to Section 2.3(f); (b) such
Product has been Manufactured in conformance with GMP, all other Applicable Law, this Agreement and the Quality Agreement; (c) title to such Product will pass to Actavis free and clear of any security interest, lien or other encumbrance;
(d) such Product has been Manufactured in facilities that are in compliance with all Applicable Law at the time of such Manufacture (including applicable inspection requirements of FDA and other Regulatory Authorities); (e) the expiration
date of such Product is no earlier than the later of (i) twenty-four (24) months (or such longer period as may be supported by subsequent stability studies) after the date the Manufacture of such Product commenced and (ii) twenty
(20) months after the date of delivery; (f) such Product has not been adulterated or misbranded under the Federal Food, Drug, and Cosmetic Act, as amended (the “FFDCA”), and similar provisions of other Applicable Law; and
(g)
  
 [*] Confidential treatment requested; certain information
omitted and filed separately with the SEC. 

  
 -13-

 
neither Novel nor any of its Affiliates has been debarred or is subject to debarment pursuant to Section 306 of the FFDCA or listed on either Excluded List. 

(b) In connection with each delivery of Product to Salix hereunder, Actavis hereby represents and warrants to Salix as of the time of the
delivery of such Product to Salix that title to such Product will pass to Salix free and clear of any security interest, lien or other encumbrance. 
 2.8 Failure or Inability to Supply Product. 
 (a) In the event that Novel,
at any time during the Term, shall have reason to believe that it will be unable to deliver the full quantity of Product forecasted to be ordered or actually ordered by Salix in a timely manner and in conformity with the warranty set forth in
Section 2.7 (whether by reason of force majeure or otherwise), Novel shall, as promptly as possible, notify Salix thereof (and, in any event, shall use its best efforts to provide at least [*] ([*]) days’ advance notice thereof to Salix);
and in the event that Actavis, at any time during the Term, shall have reason to believe that Novel will be unable to deliver the full quantity of Product forecasted to be ordered or actually ordered by Salix in a timely manner and in conformity
with the warranty set forth in Section 2.7 (whether by reason of force majeure or otherwise), Actavis shall, as promptly as possible, notify Salix thereof (and, in any event, shall use its best efforts to provide at least [*] ([*]) days’
advance notice thereof to Salix). Promptly after the giving of any notice contemplated by the previous sentence, the Parties shall meet to discuss how Salix shall obtain such full quantity of conforming Product. Compliance by Novel or Actavis with
this Section 2.8(a) shall not relieve Novel or Actavis of any other obligation or liability under this Agreement, including any obligation or liability under Section 2.8(b) or (c). 

(b) Subject to Sections 2.8(e) and 8.2, if Novel fails to deliver the full quantity of Product specified in a Purchase Order by [*] ([*])
days after the required delivery date specified therein and in conformity with the warranty set forth in Section 2.7, then Salix may, at its option, (i) cancel any portion of such Purchase Order which is not delivered by such date, in
which event Salix shall have no liability with respect to the portion of such Purchase Order so cancelled, or (ii) accept late delivery of all or any portion of the Product specified in such Purchase Order, in which event the Per-Unit Supply
Price otherwise payable by Salix to Actavis with respect to all Product accepted by Salix at least [*] ([*]) days after the required delivery date specified under such Purchase Order shall be reduced by [*] percent ([*]%). 

(c) Subject to Sections 2.8(e) and 8.2, if Novel fails to deliver the full quantity of Product specified in a Purchase Order by [*] ([*])
days after the required delivery date specified therein and in conformity with the warranty set forth in Section 2.7, then Salix may, at its option, (i) accept late delivery of all or any portion of the Product specified in such Purchase
Order, in which event the Per-Unit Supply Price 
  
 [*] Confidential
treatment requested; certain information omitted and filed separately with the SEC. 

  
 -14-

 
otherwise payable by Salix to Actavis with respect to all Product accepted by Salix under such Purchase Order shall be reduced by [*] percent ([*]%) or (ii) provide written notice to Actavis
and Novel of its intention to qualify a third party manufacturer for Product, in which event Novel shall use its best efforts promptly to assist Salix to qualify such third party manufacturer designated by Salix to Manufacture Product, and shall
promptly grant to such third party manufacturer, on a royalty-free, non-exclusive basis, such licenses, and provide to such third party manufacturer, free of charge, such technical assistance, as such third party manufacturer may require in order to
Manufacture Product to the then-current Specifications in accordance with the then-current Manufacturing process for Product, including full technology transfer of the then-current Manufacturing processes for Product, as well as, at Salix’s
option, sell to Salix, at Novel’s cost, such inventories of Materials as are necessary to effect such qualification and technology transfer and enable Salix to obtain an uninterrupted supply of Product, in all cases solely for use by Salix in
its production of Product. For purposes of clarity, Salix may qualify a third party manufacturer for Product. 
 (d) In the
event that Salix determines, within [*] ([*]) days after delivery thereof (or within [*] ([*]) days after discovery of any nonconformity that could not reasonably have been detected by a customary visual inspection on delivery), that any Product
supplied hereunder does not conform to the warranty set forth in Section 2.7, Salix shall give Actavis and Novel notice thereof (including a sample of such Product, if applicable). Novel shall undertake appropriate evaluation of such sample and
shall notify Salix and Actavis whether it has confirmed such nonconformity within [*] ([*]) days after receipt of such notice from Salix. If Novel notifies Salix and Actavis that it has not confirmed such nonconformity, the Parties shall submit the
dispute to an independent testing laboratory or other appropriate expert mutually acceptable to the Parties (the “Testing Laboratory”) for evaluation. All Parties shall cooperate with the Testing Laboratory’s reasonable
requests for assistance in connection with its evaluation hereunder. The findings of the Testing Laboratory shall be binding on the Parties, absent manifest error. The expenses of the Testing Laboratory shall be borne by Actavis and Novel if the
testing confirms the nonconformity and otherwise by Salix. If the Testing Laboratory or Novel confirms that a lot of Product does not conform to the warranty set forth in Section 2.7, Actavis and Novel, at Salix’s option, promptly shall
(i) supply Salix with a conforming quantity of Product at the expense of Actavis and Novel or (ii) reimburse Salix for the Per-Unit Supply Price paid by Salix with respect to such nonconforming Product if already paid. In addition, Actavis
and Novel promptly shall reimburse Salix for all costs incurred by Salix with respect to such nonconforming Product. Salix shall have the right to offset any such costs against any payments owed by Salix to Actavis or Novel under this Agreement.
Novel immediately shall notify Salix and Actavis if at any time it discovers that any Product delivered hereunder does not conform to the warranty set forth in Section 2.7. 

(e) The rights and remedies provided in this Section 2.8 shall be cumulative and in addition to any other rights or remedies that
may be available to Salix. 
  
 [*] Confidential Treatment requested;
certain information omitted and filed separately with the SEC. 

  
 -16-

  
 2.9Additional
Payments. Salix shall make two (2) payments to Novel, for the benefit of Actavis and Novel as may be agreed between them, for the purposes of scale-up and the qualification of the Facility, and defraying certain legal and other expenses
relating to this Agreement, the Settlement Agreement, and the Sublicense Agreement. These payments shall consist of (a) a payment of [*] United States Dollars ($[*]) within [*] ([*]) Business Days of the [*], and (ii) a payment of [*]
United States Dollars ($[*]) on [*]. These payments shall be made by wire transfer of immediately available funds to an account designated in writing by Novel. 
 2.10 Current Capacity and Scale-Up Plans. 
 (a) Novel represents and
warrants to Salix that Novel’s Capacity as of the Effective Date is as set forth on Schedule 2.10(a) (the “Current Capacity”). 
 (b) Novel agrees that at all times during the Term it will not, unless otherwise agreed in writing by Salix, allow its Capacity to be less than the Current Capacity or any increased capacity that Novel
may subsequently agree to make available for the Manufacture of the Product. 
 (c) In the event that at any time during the
Term Salix contemplates that its annual requirements of Product are likely to exceed the Current Capacity (or any increased Capacity as of such date), Salix shall promptly notify Actavis and Novel of that fact and the Parties shall thereafter
discuss in good faith plans to increase Novel’s Capacity in respect of the Product so as to meet Salix’s anticipated needs (as mutually agreed upon in writing, the “Scale-Up Plans”). Novel agrees to implement any mutually
agreed upon Scale-Up Plan as promptly as possible. 
 (d) As of [*] ([*]) days prior to the [*], Novel shall provide Salix with
a certificate that, to the best of its knowledge, it will have sufficient Capacity as of the Supply Term Commencement Date (or, if later, the anticipated Qualification Date) to fulfill its supply obligations hereunder. 

(e) Schedule 2.10(e) reflects the equipment that Novel anticipates it will need to obtain, and the associated out-of-pocket
transportation, installation, qualification, validation and site preparation costs that it will incur, in order to outfit the Facility to meet Salix’s current specific requirements in respect of the Manufacture of the Product. Within [*] ([*])
business days of the [*], Salix shall advance the amount specified in Schedule 2.10(e) to Novel for such purposes. Novel shall purchase all such equipment in Salix’s name. Within [*] ([*])] days of the date Novel has outfitted the
Facility to meet Salix’s current specific requirements in respect of the Manufacture of the Product, Novel shall provide Salix with an accounting of the cost of such equipment and associated out-of-pocket costs of transportation, installation,
qualification, validation and site preparation that were incurred by Novel in connection with this task, accompanied by 
  

[*] Confidential Treatment requested; certain information omitted and filed separately with the SEC. 

  
 -16-

 
appropriate supporting documentation, and a refund of any portion of such advance not spent for such purposes prior to such date of outfitting. In respect of the equipment, Novel agrees as
follows: (i) the equipment shall at all times remain the property of Salix, and Novel shall have no right, title or interest therein; (ii) Novel shall not remove or permit the taking of the equipment from the Facility without Salix’s
prior written consent; (iii) Novel shall indemnify Salix against all claims directly or indirectly arising out of or connected with its use or custody of such equipment; (iv) Novel shall cooperate with Salix in making any protective
filings under the Uniform Commercial Code as may be required, in Salix’s sole judgment, to verify, protect and preserve Salix’s interest in such equipment from the claims of third parties; (v) Novel shall, upon the request of Salix
and at Novel’s expense, firmly and conspicuously affix to such equipment such decals or labels as are supplied by Salix showing Salix as the owner of the equipment; (vi) Novel shall make any alterations to such equipment that may be
required by Salix or legally necessary, with prior written consent from Salix and necessary documentation, and make no other alterations to the equipment (except for alterations or additions that will not impair the value or performance of such
equipment and that are readily removable without damage to the equipment); (vii) Novel shall use, maintain and operate such equipment lawfully, exclusively for the purpose for which it was designed, and so as to cause such equipment to be in
good repair and operating condition and in at least the same condition as when delivered to Novel hereunder, except for ordinary wear and tear; (viii) Novel shall at all times protect and defend, at its own cost and expense, the title of Salix
in and to such equipment from and against any and all claims, liens and legal processes of creditors of Novel; (ix) with reasonable prior notice to Novel, Salix shall have the right from time to time (but no more than twice in each Calendar
Year) during reasonable business hours to enter the Facility to inspect such equipment and Novel’s applicable maintenance records for the purpose of confirming the existence, condition and proper maintenance of such equipment; and (x) such
equipment shall at all times remain personal property, notwithstanding that such equipment, or any part thereof, may be affixed or attached to real property or any improvements thereon. Novel shall have the right to use such equipment for purposes
other than the Manufacture of Product hereunder, without rent, provided that such use does not interfere with the Manufacture of Product hereunder in a timely manner and otherwise in compliance with the provisions of this Agreement. Upon termination
of this Agreement, Novel shall have the right to purchase the equipment from Salix for its fair market value at that time. That value shall initially be determined by an independent third party used equipment appraisal obtained by Novel, at
Novel’s expense. Salix shall have [*] ([*]) days to determine, and notify, Novel whether it accepts the Novel appraisal or will obtain its own independent third party used equipment appraisal of the equipment, at Salix’s expense. If Salix
disputes the Novel appraisal and provides its own appraisal, then Novel shall have [*] ([*]) days from its receipt of the Salix appraisal to accept that appraisal or to engage a third appraisal, using an appraiser jointly selected and engaged by
Salix and Novel, at their shared expense, whose determination shall be binding, absent manifest error. If a third appraisal is engaged, then Novel shall have [*] ([*]) days from the delivery of such appraisal to determine and notify Salix whether it
will purchase the equipment at the valuation 
  
 [*] Confidential Treatment requested; certain information omitted and filed separately with the SEC. 

  
 -17-

 
determined in such third appraisal. If Novel agrees to purchase the equipment from Salix in accordance with the foregoing, then Salix and Novel shall complete such purchase within [*] ([*]) days.
If Novel determines that it does not wish to purchase the equipment or fails to give Salix timely notice as contemplated by the preceding sentences, then Novel shall, at its expense, de-install, inspect, test, properly pack and return any equipment
purchased by Salix under this Section 2.10(e) (but not the Facility’s related fixtures and equipment, such as air handlers), free of all liens and rights of others, by delivering it to Salix EXW the Facility (Incoterms 2000). 

2.11 Costs and Expenses. Except as otherwise explicitly set forth herein, Novel shall be solely responsible for all costs and
expenses incurred in connection with Qualification and the Manufacture of Product hereunder, including costs and expenses of personnel, quality control testing, Manufacturing facilities and equipment, and Materials. 

2.12 Amendment of Specifications. 
 (a) Salix may amend, modify or supplement the Specifications, the Manufacturing process, or the test methods for the Product unilaterally and in its sole discretion (i) at any time, for the purpose
of complying with any Regulatory Approval, GMP and all other Applicable Law and compendia or, (ii) upon [*] ([*]) days’ prior written notice (or such longer notice period as may be agreed in writing by the Parties in order to permit Novel
sufficient time to implement such changes in a commercially reasonable time frame) for any other purpose. Salix promptly shall provide Novel and, upon request, Actavis, with appropriate documentation relating to any such changes. 

(b) Actavis and Novel shall not in any respect amend, modify or supplement the Specifications, the Manufacturing process, or the test
methods for Product or any Materials or sources of Materials used in connection with Manufacturing Product without the prior written consent of Salix. 
 (c) In the event that any amendment to the Specifications, the Manufacturing process, or the test methods for Product adversely affects Novel’s ability to maintain its Capacity at the Current
Capacity (or any increased capacity available to Novel as of the Supply Term Commencement Date (or, if later, the Qualification Date) or as subsequently agreed pursuant to a Scale-Up Plan) the Parties shall discuss in good faith a Scale-Up Plan to
address such shortfall in Capacity and Novel shall implement any mutually agreed Scale-Up Plan as promptly as possible. 
 (d)
Salix shall reimburse Novel for reasonable expenses or increased costs that are actually incurred by Novel in connection with any amendment of the Specifications or the Manufacturing process for the Product required by Salix pursuant to
Section 2.12(a), including reasonable costs of capital equipment and process upgrades and obsolescence of Materials, goods-in-process, and finished goods not suitable for 
 [*] Confidential Treatment requested; certain information omitted and filed separately with the SEC. 

  
 -18-

 
other use in the business or operations of Novel or any of its Affiliates; provided, however, that Salix’s liability for such reimbursement shall be limited to levels of
inventory that are consistent with the most recent Firm Forecast; and further provided, that Salix and Novel shall engage in good faith discussions regarding the amount of such expenses. 

(e) Novel shall be solely responsible for any and all increased costs or out-of-pocket expenses incurred by it or Salix as a result of
any amendment of the Specifications or the Manufacturing process for Product (i) requested by Novel and consented to in writing by Salix or (ii) required by Salix as a result of Novel’s failure to Manufacture Product in conformity
with the warranty set forth in Section 2.7. 
 2.13 Quality Agreement. Within [*] ([*])] days after the [*], and in
any event prior to any commercial sale of Product, the Parties shall prepare and enter into a reasonable and customary quality assurance agreement that shall set forth the terms and conditions upon which Actavis and Novel will conduct their quality
activities in connection with this Agreement (the “Quality Agreement”). Each Party shall duly and punctually perform all of its obligations under the Quality Agreement. 

2.14 Quality Control Analyses and Release. 
 (a) Novel shall be responsible for all quality control analyses of Materials and Product. 
 (b) All Product shall be released by Novel, in each case in accordance with the terms of the Quality Agreement, prior to final release by Salix. 

2.15 Maintenance of Facility. 
 (a) Except as otherwise approved in writing by Salix, Actavis shall have the Product Manufactured exclusively by Novel and Novel shall Manufacture the Product exclusively at the Facility. 

(b) Novel shall ensure that any and all licenses, registrations, and Regulatory Authority approvals required by Applicable Law to be
obtained in connection with the Facility and equipment used in connection with the Manufacture of Product by Novel so as to permit Novel to Manufacture Product and have it supplied by Actavis to Salix as contemplated hereunder have been obtained and
are in all respects current and in full force and effect. 
  
 [*]
Confidential Treatment requested; certain information omitted and filed separately with the SEC. 

  
 -19-

  
 (c) Novel shall at all
times during the Term maintain the Facility and such equipment in a state of repair and operating efficiency consistent with the requirements of the Specifications, GMP and all other Applicable Law. 

(d) Novel shall maintain in the Facility adequate holding accommodations for Product manufactured for Salix hereunder and the Materials
used in Manufacturing Product for Salix hereunder as and to the extent required by the Specifications, GMP and all other Applicable Law. 
 (e) Novel shall only use disposal services or sites that have appropriate environmental permits and are in compliance with Applicable Law. 

2.16 Regulatory Cooperation of Actavis and Novel. Actavis and Novel shall cooperate with any reasonable requests for assistance
from Salix with respect to obtaining and maintaining any and all Regulatory Approvals required in connection with the sourcing of Product by Salix hereunder and the sale of Product in the Territory, including by: 

(a) at Actavis’s or Novel’s own cost (as the case may be), making its employees, consultants and other staff available upon
reasonable notice during normal business hours to attend meetings with Regulatory Authorities concerning Materials or Product or any component or intermediate thereof; and 
 (b) at Actavis’s or Novel’s own cost (as the case may be), disclosing and making available to Salix, in whatever form Salix may reasonably request, all Manufacturing and quality control data,
CMC Data and other information related to Materials or Product or any component or intermediate thereof and the Manufacturing process therefor as is reasonably necessary or desirable to prepare, file, obtain and maintain any Regulatory Approval
required in connection with the sourcing of Product by Salix hereunder and the sale of Product in the Territory. 
 2.17
Inspection by Salix. Novel agrees that Salix and its agents (so long as such agents have entered into binding confidentiality agreements with Salix providing for obligations no less strict than Salix’s confidentiality obligations to
Novel hereunder) shall have the right, as required by Applicable Law or otherwise once each Calendar Year, or otherwise for cause, upon reasonable prior notice to Novel and during normal business hours, to inspect the Facility as well as the
Manufacturing of Product and any component or intermediate thereof, including inspection of (a) Materials, (b) the holding facilities for Materials or Product or any component or intermediate thereof, (c) the equipment used in the
Manufacture of Product or any component or intermediate thereof, and (d) all records relating to such Manufacturing and the Facility (to the extent they relate to Product or any component or intermediate thereof). Following such audit, Salix
shall discuss its observations and conclusions with Novel and Novel shall implement such corrective actions as may be 

 

  

 
reasonably determined by Salix within [*] ([*]) days after notification thereof by Salix or such longer period as may be agreed by Salix and Novel. 

2.18 Notification of Regulatory Inspections; Communications. 

(a) Novel shall notify Salix by telephone within twenty-four (24) hours, and in writing within two (2) Business Days, after
learning of any proposed visit to, or inspection of, the Facility by any Regulatory Authority and immediately by telephone after learning of any unannounced visit to, or inspection of, the Facility by any Regulatory Authority if such visit or
inspection primarily relates to the Facility’s compliance with GMP, the Manufacture of the Product, or the Manufacture of any other product containing polyethylene glycol 3350 as an active pharmaceutical ingredient. Novel shall also notify
Salix by telephone within twenty-four (24) hours, and in writing within two (2) Business Days, if the visit to, or inspection of, the Facility by such Regulatory Authority becomes directed towards the Facility’s compliance with GMP,
the Manufacture of the Product, or the Manufacture of any other product containing polyethylene glycol 3350 as an active pharmaceutical ingredient. 
 (b) In the case of any such visit or inspection that relates to the Facility’s compliance with GMP in respect of the Manufacture of the Product or directly to the Manufacture of the Product, Novel
shall permit Salix or its agents to be present and participate in such visit or inspection. 
 (c) Novel shall provide to Salix
a copy of (i) any report and other written communication (or the relevant portions thereof) received from such Regulatory Authority in connection with a visit to or inspection of the Facility that relates to compliance with GMP in respect of
the Manufacture of the Product or directly to the Manufacture of the Product; (ii) any warning letters or similar communications from a Regulatory Authority in respect of the Facility; and (iii) any written communications received from a
Regulatory Authority relating to the Facility’s compliance with GMP in respect of the Manufacture of the Product or directly to the Manufacture of the Product or any component or intermediate thereof or any equipment or Manufacturing process
used in connection with the Manufacture of Product or any component or intermediate thereof, in each case within [*] ([*]) Business Days after receipt thereof. Novel shall consult with Salix concerning the response of Novel to each such
communication. Novel shall provide Salix with a copy of all draft responses for comment as soon as possible and all final responses for review and approval, which shall not be unreasonably withheld, conditioned or delayed, within [*] ([*]) Business
Days prior to submission thereof. 
 2.19 Recalls and Withdrawals. 

(a) Actavis and Novel jointly and severally agree promptly to reimburse Salix for any and all documented out-of-pocket costs reasonably
incurred by Salix with 
  
 [*] Confidential Treatment requested;
certain information omitted and filed separately with the SEC. 

  
 -21-

 
respect to recalls and market withdrawals of Product, including associated retrieval of Product, returns of Product, destruction of Product, replacement of Product, and fees and penalties owed to
third parties, as and to the extent such recalls or market withdrawals result from breach of the obligations of Actavis or Novel under this Agreement or the negligence or willful misconduct of Actavis or Novel. Salix shall have the right to offset
any such costs against any payments owed by Salix to Actavis or Novel under this Agreement. 
 (b)
Notwithstanding anything else in this Agreement to the contrary, (i) Actavis’s and Novel’s joint liability to Salix pursuant to Section 2.19(a) in respect of any one recall or market withdrawal event shall not exceed [*] United
States Dollars ($[*]), and (ii) Salix acknowledges and agrees that Actavis’s and Novel’s sole liability to Salix for costs of the type identified in Section 2.19(a) shall be as set forth in this Section 2.19. 

(c)For the avoidance of doubt, [*] shall be considered “one recall or market withdrawal event.” 

2.20 Compliance with Applicable Laws. 
 (a) Novel shall strictly comply, and shall cause each of its Materials suppliers to strictly comply, with GMP and all other Applicable Law in carrying out the Manufacturing of Product and any component or
intermediate thereof and its other duties and obligations under this Agreement. Upon Salix’s request, Novel shall certify in writing its compliance with this Section 2.20(a) and shall provide all permits, certificates and licenses that may
be required for its performance under this Agreement. 
 (b) Actavis shall strictly comply with all Applicable Law in carrying
out its obligations to supply Product and its other duties and obligations under this Agreement. Upon Salix’s request, Actavis shall certify in writing its compliance with this Section 2.20(b) and shall provide all permits, certificates
and licenses that may be required for its performance under this Agreement. 
 2.21 Retention of Manufacturing Records and
Samples. 
 (a) Novel shall generate, retain and maintain, both during the Term and thereafter: 

(i) all records necessary to comply with GMP and all other Applicable Law relating to the Manufacture of Product or any component or
intermediate thereof. Without limiting the foregoing, records shall be made concurrently with the performance of each step in the Manufacture of Product and in such a manner that at any time successive steps in the Manufacture and distribution of
any batch may be traced by an inspector. Such records shall be legible and indelible, shall identify the Person 
  
 [*] Confidential Treatment requested; certain information omitted and filed separately with the SEC. 

  
 -22-

 
immediately responsible, shall include dates of the various steps and be as detailed as necessary for a clear understanding of each step by an individual experienced in the manufacture of
pharmaceutical products; 
 (ii) all Manufacturing records, standard operating procedures, equipment log books, batch
manufacturing records, laboratory notebooks and all raw data relating to the Manufacturing of Product and any component or intermediate thereof; 
 (iii) samples of each batch and Materials. Samples shall include a quantity of representative material of each batch and Materials sufficient to perform at least full duplicate quality control testing,
and shall specify the dates of Manufacture and packaging thereof. Samples so retained shall be selected at random from either final container material or from bulk and final containers; provided that they include at least one final container
as a final package, or package-equivalent of such filling of each batch. Such sample shall be stored at temperatures and under conditions which will maintain the identity and integrity of the relevant sample; and 

(iv) such other records and samples as Salix reasonably may require in order to ensure compliance by Novel with the terms of this
Agreement and Applicable Law. 
 (b) Without prejudice to Novel's obligations pursuant to Section 2.21(a), Novel shall
diligently complete the master batch record for Product during the Manufacture of such Product. 
 (c) Actavis shall generate,
retain and maintain, both during the Term and thereafter, such records in respect of its activities under this Agreement as may be required by Applicable Law and such other records as Salix may reasonably require in order to ensure compliance by
Actavis with the terms of this Agreement and Applicable Law. 
 (d) All Materials, samples, records and other items referred to
in Section 2.21(a), (b), and (c) shall be retained by Actavis or Novel, as applicable, for the longer of (i) such period as may be required by GMP and all other Applicable Law and (ii) five (5) years. 

2.22 Exclusive Supply Arrangement. For as long as there is at least one Valid Claim in the Territory for any Product Patent, then,
to the maximum extent permitted by Applicable Law, except only as and to the extent contemplated by the Settlement Agreement and the Sublicense Agreement, Actavis and Novel shall not, and Actavis and Novel shall cause their respective Affiliates not
to, distribute, market, promote, offer for sale, sell or otherwise supply Product, Covered Product or any generic versions thereof, directly or indirectly, whether at wholesale or retail, to any Person other than Salix or its Affiliates.

  
 -23-

 
The limitation of this Section 2.22 shall terminate as of the end of the Term or upon a Settlement Termination Event, as such term is defined in the Settlement Agreement. 

2.23 Second Source. 
 (a) Salix shall have the right to secure a second source of Product. Novel shall promptly grant to such third party manufacturer as may be designated by Salix as a second source of Product, on a
royalty-free, non-exclusive basis, such licenses, and provide to such third party manufacturer, free of charge, such technical assistance, as such third party manufacturer may require in order to Manufacture Product to the then-current
Specifications in accordance with the then-current Manufacturing process for Product, including full technology transfer of the then-current Manufacturing processes for Product, as well as, at Salix’s option and cost, such excess inventories of
Materials as are necessary to effect such technology transfer and enable Salix to obtain an uninterrupted supply of Product, in all cases solely for use by Salix in its production of Product. 

(b) The qualification of a second source of Product pursuant to this Section 2.23 shall not alter or qualify Salix’s
obligations in respect of the purchase of Product hereunder.  
 ARTICLE III. INTELLECTUAL PROPERTY

 3.1 Ownership of Inventions. 
 (a) Except as otherwise expressly provided in this Article III, each Party shall own all right, title and interest in and to any Inventions that are conceived, discovered, developed or otherwise made
exclusively by or on behalf of such Party or its Affiliates, employees or contractors in performing such Party’s obligations hereunder or in respect of such Party’s activities in respect hereof. Salix hereby grants to Novel a royalty-free,
non-exclusive license to use all such right, title and interest in and to any such Inventions that Salix may develop for the sole purpose of performing Novel’s obligations hereunder or exercising Novel’s rights hereunder. Actavis and Novel
hereby grant to Salix an irrevocable, perpetual, fully paid-up, royalty-free, non-exclusive license, with the right to enforce and to grant sublicenses through multiple tiers, to use all such right, title and interest in and to any such Inventions
that either of them may develop relating to the Product (“Product Inventions”). 
 (b) Those Parties
conceiving, discovering, developing or otherwise making a Joint Invention shall jointly own all right, title and interest in and to such Joint Invention. Actavis and Novel shall, and do hereby, grant to Salix an irrevocable, perpetual, fully
paid-up, royalty-free, non-exclusive license, with the right to grant sublicenses through multiple tiers, under all of their right, title and interest in and to all 

  
 -24-

 
Joint Inventions to Exploit the Product. Salix shall, and does hereby, grant such of Actavis and Novel as may have been involved, directly or through an Affiliate, in conceiving, discovering,
developing or otherwise making a Joint Invention an irrevocable, perpetual, fully paid-up, royalty-free, non-exclusive license, with the right to grant sublicenses through multiple tiers, under all of Salix's right, title and interest in and to the
Joint Invention to Exploit the Product. Each of Salix, on the one hand, and Actavis and Novel, on the other hand, shall, and shall cause its Affiliates to, promptly disclose in writing to the other the discovery, development, making, conception or
reduction to practice of any Joint Invention. 
 3.2 Prosecution of Invention Patents. Salix shall have the first right,
but not the obligation, to prepare, file, prosecute and maintain any patent applications and patents covering Joint Inventions and Product Inventions (collectively, the "Invention Patents," and each, an "Invention Patent") and shall be
responsible for related interference, re-issuance, re-examination and opposition proceedings; provided, however, that if Salix plans to abandon an Invention Patent, Salix shall notify Actavis and Novel in writing at least [*] ([*])
days in advance of the due date of any payment or other action that is required to prepare, file, prosecute or maintain such Invention Patent, and Actavis and Novel or either of them may elect, upon written notice within such [*] ([*]) day period to
Salix, to make such payment or take such action, at their or its own expense, and thereafter to become the sole owners or owner of such Invention Patent. In such event, Salix shall cooperate, without additional consideration, to assign and transfer
all of its right, title and interest in and to such Invention Patent to Actavis and Novel or either of them, as the case may be, as the sole owners or owner. 
 3.3 United States Law. The determination of whether Inventions are conceived, discovered, developed or otherwise made by a Party for the purpose of allocating proprietary rights (including patent,
copyright or other intellectual property rights) therein, shall, for purposes of this Agreement, be made in accordance with applicable law in the United States. In the event that United States law does not apply to the conception, discovery,
development or making of any Invention hereunder, each Party shall, and does hereby, assign, and shall cause its Affiliates to so assign, to the other Parties, without additional compensation, such right, title and interest in and to any Inventions,
as well as any intellectual property rights with respect thereto, as necessary to fully effect ownership as contemplated by Section 3.1. 
 3.4 Corporate Names. Actavis and Novel shall, and do hereby, grant to Salix a non-exclusive, royalty-free license, with the right to grant sublicenses through multiple tiers, to use such Corporate
Names of Actavis and Novel or their Affiliates, solely as may be required by Applicable Law, in connection with Salix's sale or documentation of the chain of custody of Product in the Territory. 

 
 [*] Confidential Treatment requested; certain information omitted and filed
separately with the SEC. 

  
 -26-

  
 ARTICLE IV.
REPRESENTATIONS AND WARRANTIES; COVENANTS 
 4.1 Representations and Warranties of Each Party. Each Party hereby
represents and warrants to the other Parties as of the Effective Date as follows: 
 (a) Such Party (i) is duly formed and
in good standing under the laws of the jurisdiction of its formation, (ii) has the power and authority and the legal right to enter into this Agreement and perform its obligations hereunder, and (iii) has taken all necessary action on its
part required to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder. This Agreement has been duly executed and delivered on behalf of such Party and constitutes a legal, valid and binding
obligation of such Party and is enforceable against it in accordance with its terms, subject to the effects of bankruptcy, insolvency or other similar laws of general application affecting the enforcement of creditor rights and judicial principles
affecting the availability of specific performance and general principles of equity, whether enforceability is considered in a proceeding at law or equity. 
 (b) All necessary consents, approvals and authorizations of all regulatory and governmental authorities and other Persons required to be obtained by such Party in connection with the execution and
delivery of this Agreement and the performance of its obligations hereunder have been obtained. 
 (c) The execution and
delivery of this Agreement and the performance of such Party's obligations hereunder (i) do not and will not conflict with or violate any requirement of applicable law or any provision of the articles of incorporation, bylaws, limited
partnership agreement or other similar documents of such Party and (ii) do not and will not conflict with, violate, or breach, or constitute a default or require any consent under, any contractual obligation or court or administrative order by
which such Party is bound. 
 4.2 Additional Warranties and Covenants of Actavis and Novel. Each of Actavis and Novel
hereby represents, warrants and covenants to Salix that: 
 (a) Neither it nor any of its Affiliates has been debarred or is
subject to debarment pursuant to Section 306 of the FFDCA or listed on either Excluded List. 
 (b) Neither it nor any of
its Affiliates will use in any capacity, in connection with the services to be performed under this Agreement, any Person who has been debarred pursuant to Section 306 of the FFDCA, or who is the subject of a conviction described in such
section, or listed on either Excluded List. 

  
 -26-

  
 (c) It will inform
Salix in writing immediately if it or any Person who is performing services hereunder is debarred or is the subject of a conviction described in Section 306 of the FFDCA or listed on either Excluded List, or if any action, suit, claim,
investigation or legal or administrative proceeding is pending or, to the best of its knowledge, is threatened, relating to the debarment or conviction under Section 306 of the FFDCA, or listing on either Excluded List, of it or any Person
performing services hereunder. 
 4.3 Disclaimer of Other Warranties. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT,
THE PARTIES MAKE NO REPRESENTATIONS AND EXTEND NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE OR WARRANTY OF MERCHANTABILITY. 

ARTICLE V. CONFIDENTIALITY 
 5.1 Confidential Information. Subject to the provisions of Sections 5.2 and 5.3, at all times during the Term and for seven (7) years following the expiration or termination of this Agreement,
the Receiving Party (a) shall keep completely confidential and shall not publish or otherwise disclose any Confidential Information furnished to it by the Disclosing Party, except to those of the Receiving Party's employees, Affiliates, or
consultants who have a need to know such information to perform such Party’s obligations hereunder (and who shall be advised of the Receiving Party’s obligations hereunder and who are bound by confidentiality obligations with respect to
such Confidential Information no less onerous than those set forth in this Agreement) (collectively, “Recipients”) and (b) shall not use Confidential Information of the Disclosing Party directly or indirectly for any
purpose other than performing its obligations or exercising its rights hereunder. The Receiving Party shall be jointly and severally liable for any breach by any of its Recipients of the restrictions set forth in this Agreement. 

5.2 Exceptions to Confidentiality. The Receiving Party’s obligations set forth in this Agreement shall not extend to any
Confidential Information of the Disclosing Party: 
 (a) that is or hereafter becomes part of the public domain by public use,
publication, general knowledge or the like through no wrongful act, fault or negligence on the part of a Receiving Party or its Recipients; 
 (b) that is received from a third party without restriction and without breach of any agreement between such third party and the Disclosing Party; 

  
 -27-

  
 (c) that the Receiving
Party can demonstrate by competent evidence was already in its possession without any limitation on use or disclosure prior to its receipt from the Disclosing Party; 
 (d) that is generally made available to third parties by the Disclosing Party without restriction on disclosure; or 
 (e) that the Receiving Party can demonstrate by competent evidence was independently developed by the Receiving Party. 
 5.3 Disclosure. 
 (a) Each Party may disclose Confidential Information to
the extent that such disclosure is: 
 (i) made in response to a valid order of a court of competent jurisdiction or other
governmental body of a country or any political subdivision thereof of competent jurisdiction; provided, however, that, if permitted by law, the Receiving Party shall first have given notice to the Disclosing Party and given the
Disclosing Party a reasonable opportunity to quash such order or to obtain a protective order requiring that the Confidential Information or documents that are the subject of such order be held in confidence by such court or governmental body or, if
disclosed, be used only for the purposes for which the order was issued; and provided further that if a disclosure order is not quashed or a protective order is not obtained, the Confidential Information disclosed in response to such court or
governmental order shall be limited to that information that is legally required to be disclosed in such response to such court or governmental order; 
 (ii) made pursuant to Section 2.23; or 
 (iii) otherwise required by law or
regulation, in the opinion of legal counsel to the Receiving Party. 
 (b) Salix may disclose Confidential Information to the
extent that such disclosure is made to Regulatory Authorities as required in connection with any filing, application or request for Regulatory Approval; provided, however, that reasonable measures shall be taken to assure confidential
treatment of such information. 
 (c) To the extent, if any, that a Party concludes in good faith that it is required by
applicable laws or regulations to file, register or otherwise disclose this Agreement or Confidential Information to a governmental authority, including the FDA or the U.S. Securities and Exchange Commission, such Party may do so, and the other
Party shall cooperate in any such filing or notification, including by executing all documents reasonably required in connection therewith. In such situation, the filing Party shall request confidential treatment of sensitive provisions of the
Agreement, to the extent permitted by Applicable Law and in consultation with the other Party. The Parties 

  
 -28-

 
shall promptly inform each other as to the activities or inquiries of any such governmental authority relating to this Agreement, and shall cooperate to respond to any request for further
information therefrom. 
 (d) Novel may disclose Confidential Information to Actavis solely to the extent necessary to keep
Actavis informed with respect to the general status of its facility qualification efforts as contemplated hereby and this Agreement and quantities of Product ordered or purchased under this Agreement and amounts paid or required to be paid by Salix
therefor; provided, however, that such Confidential Information shall, following such disclosure, remain subject to this Article V in the hands of both Actavis and Novel. 

5.4 Notification. The Receiving Party shall notify the Disclosing Party immediately, and cooperate with the Disclosing Party as
the Disclosing Party may reasonably request, upon the Receiving Party's discovery of any loss or compromise of the Disclosing Party’s Confidential Information. 
 5.5 Remedies. Each Party agrees that the unauthorized use or disclosure of any information by the Receiving Party in violation of this Agreement will cause severe and irreparable damage to the
Disclosing Party. In the event of any violation of this Article V, the Receiving Party agrees that the Disclosing Party shall be authorized and entitled to obtain from any court of competent jurisdiction injunctive relief, whether preliminary or
permanent, without the necessity of proving irreparable harm or monetary damages, as well as any other relief permitted by applicable law. The Receiving Party agrees to waive any requirement that the Disclosing Party post bond as a condition for
obtaining any such relief. 
 5.6 Use of Names. No Party shall mention or otherwise use the name, insignia, symbol,
trademark, trade name or logotype of any other Party (or any abbreviation or adaptation thereof) in any publication, press release, promotional material or other form of publicity without the prior written approval of such other Party in each
instance. The restrictions imposed by this Section 5.6 shall not prohibit any Party from making any disclosure identifying another Party that is required by Applicable Law; provided, however, that reasonable measures shall be
taken to assure confidential treatment of such information. 
 5.7 Press Releases. Except as expressly provided in
Section 5.3, no Party shall make a press release or other public announcement regarding this Agreement, the terms hereof or the transactions contemplated hereby without the prior written approval of the other Parties. Each Party shall provide
the others with the proposed text of any such press release or public announcement for review and approval, which approval shall not be unreasonably withheld, conditioned or delayed, as early as possible, but in no event less than four
(4) Business Days in advance of the publication, communication or dissemination thereof; provided, however, that a receiving Party shall be deemed to have approved any such 

  
 -29-

 
press release or public announcement if it fails to notify the proposing Party in writing of any objections to such press release or public announcement within three (3) Business Days after
receipt by the receiving Party of the text of such public announcement. 
 ARTICLE VI. TERM AND TERMINATION 

6.1 Term. The term of this Agreement (the “Term”) shall commence as of the Effective Date and, unless earlier
terminated in accordance with the terms hereof, shall, unless otherwise directed by notice given by Salix to Actavis and Novel, expire on the earlier of: 
 (a) the first date on which there is no longer (i) a Product Patent that includes at least one Valid Claim in the Territory or (ii) any Data Exclusivity with respect to the Product in the
Territory; provided, however, that if Salix or, to Salix’s knowledge, Norgine intends to withdraw all of the Product Patents, Salix shall give Actavis and Novel [*] ([*]) days’ notice prior to withdrawal; and 

(b) the Start Date (as such term is defined in the Sublicense Agreement). 

6.2 Termination. In addition to any other provision of this Agreement expressly providing for termination of this Agreement, this
Agreement may be terminated as follows: 
 (a) By Salix. Salix may terminate this Agreement immediately upon notice to
Actavis and Novel 
 (i)in the event that Regulatory Authorities require or cause the permanent and full withdrawal of Product
from the Territory (it being acknowledged and agreed that in the event that Regulatory Authorities require or cause a temporary withdrawal of Product from the Territory, this Agreement will be suspended until the Product is once again permitted to
be marketed, but it will not in such circumstances be terminated); 
 (ii) in the event that a Settlement Termination Event (as
such term is defined in the Settlement Agreement) occurs; 
 (iii) in the event that, following Salix’s exercise of its
rights under the first sentence of Section 6.4(b), Actavis or such third party manufacturer as shall have been designated by Actavis and approved by Salix in accordance with the provisions of Section 6.4(b) shall not within [*] ([*]) days
following the date of the notice given by Salix pursuant to the first sentence of Section 6.4(b) have achieved qualification to supply Product to Salix as contemplated by Section 2.1, so long as such failure is not 

 
 [*] Confidential Treatment requested; certain information omitted and filed
separately with the SEC. 

  
 -30-

 
attributable to any material extent to the failure of Salix to have fulfilled its obligations under Section 6.4(b); 
 (iv) in the event of any material breach by either Actavis or Novel in the performance of any of its obligations herein contained that (if curable) has not been cured by the defaulting Party within
(a) in the case of any material breach other than one involving failure to make a payment required under this Agreement, [*] ([*]) days after receiving written notice thereof from Salix; and (b) in the case of any material breach involving
a failure to make a payment required under this Agreement, [*] ([*]) days after receiving written notice thereof from Salix; or 
 (v) as provided in Section 6.4(c). 
 (b) By Actavis and Novel. This
Agreement may be terminated by Actavis and Novel, acting together: 
 (i) immediately upon written notice to Salix if Salix
shall 
 (A) file in any court or agency pursuant to any statute or regulation of any state, country or jurisdiction a petition
in bankruptcy or insolvency or for reorganization or for arrangement or for the appointment of a receiver or trustee of Salix or of its assets, 
 (B) propose a written agreement of composition or extension of its debts, 
 (C)
be served with an involuntary petition against it, filed in any insolvency proceeding, and such petition shall not be dismissed within sixty (60) days after the filing thereof, 

(D) propose or be a party to any dissolution or liquidation, 
 (E) make an assignment for the benefit of its creditors, or 
 (F) admit in
writing its inability generally to pay its debts as they fall due in the general course; 
 (ii) immediately upon written
notice to Salix in the event of any material breach by Salix in the performance of any of its obligations herein contained that (if curable) has not been cured by Salix within (a) in the case of any material breach other than one involving
failure to make a payment required under this Agreement, [*] ([*]) days after receiving written notice thereof from Actavis and Novel; and (b) in the case of any material breach involving a failure to make a payment required under this
Agreement, [*] ([*]) days after receiving written notice thereof from Actavis and Novel. 
  
 [*] Confidential Treatment requested; certain information omitted and filed separately with the SEC. 

  
 -31-

  
 (c) By Any
Party. This Agreement may be terminated by any Party: 
 (i) immediately upon written notice to the other Parties in the
event that, as a result of an order of government or any other official authority, the continued operation of this Agreement in its entirety or in substantial part is prohibited or prevented; or 

(ii) as provided in Section 8.2. 
 6.3 Effect of Expiration or Termination. 
 (a) The expiration or earlier
termination of this Agreement shall be without prejudice to any rights or obligations of the Parties that may have accrued prior to such termination, and the provisions of Sections 2.5, 2.7, 2.10(e), 2.14, 2.16, 2.19, 2.21, Articles III, IV and V,
this Article VI, Article VII and Article VIII shall survive the expiration or termination of this Agreement. Except as otherwise expressly provided herein, termination of this Agreement in accordance with the provisions hereof shall not limit
remedies that may otherwise be available at law or in equity. 
 (b) Upon expiration or earlier termination of this Agreement,
each Party, at the request of another, shall return all data, files, records and other materials in its possession or control containing or comprising the requesting Party’s Confidential Information except that the legal department of such
Party may retain one copy for archival purposes. 
 (c) Upon expiration of this Agreement or any earlier termination of this
Agreement by Salix pursuant to Section 6.2(a)(iii) or (iv) or (v) or (c), then, at Salix’s option, Novel shall use its best efforts promptly to assist Salix to qualify a third party manufacturer designated by Salix to
Manufacture Product to meet Salix’s requirements, in which event Novel shall use its best efforts promptly to assist Salix to qualify such third party manufacturer to Manufacture Product, and shall promptly grant to such third party
manufacturer, on a royalty-free, non-exclusive basis, such licenses, and provide to such third party manufacturer, free of charge in the event of a termination of this Agreement by Salix pursuant to Section 6.2(a)(iii), (iv) or (v) or
(c) and at Novel’s standard time and materials cost in the event of an expiration of this Agreement, such technical assistance, as such third party manufacturer may require in order to Manufacture Product to the then-current Specifications
in accordance with the then-current Manufacturing process for Product, including full technology transfer of the then-current Manufacturing processes for Product, as well as, at Salix’s option and cost, such inventories of Materials as are
necessary to effect such qualification and technology transfer and enable Salix to obtain an uninterrupted supply of Product, in all cases solely for the purposes of Salix’s production of Product. 

 

  

  
 (d) Upon any
termination of this Agreement by Salix pursuant to Section 6.2(a)(i) or (ii) or by Actavis and Novel pursuant to Section 6.2(b) or by Actavis or Novel pursuant to Section 6.2(c), Salix shall (i) purchase from Actavis the
amount of Product that is subject to Purchase Orders outstanding at the time of such termination; (ii) reimburse Novel for work in process and Materials that Novel has purchased for the purpose of supplying Product in accordance with this
Agreement; and (iii) pay Novel’s [*] for any such work in process and Novel’s [*] from its suppliers for any such Materials. 
 (e) Except as and to the extent contemplated by Section 6.3(d), upon expiration of this Agreement or any earlier termination of this Agreement, Novel immediately shall cease all Manufacturing of
Product pursuant to this Agreement, and all existing Purchase Orders shall, at Salix’s option, be deemed canceled. 
 (f)
Following expiration or termination of this Agreement, Actavis and Novel shall provide such reasonable cooperation and support with respect to regulatory matters as Salix may require in order to dispose of previously purchased Product. 

6.4 Bankruptcy of Actavis or Novel. 
 (a) In the event Actavis shall 
 (i) file in any court or agency pursuant to any
statute or regulation of any state, country or jurisdiction a petition in bankruptcy or insolvency or for reorganization or for arrangement or for the appointment of a receiver or trustee of Actavis or of its assets, 

(ii) propose a written agreement of composition or extension of its debts, 

(iii)be served with an involuntary petition against it, filed in any insolvency proceeding, and such petition shall not be dismissed
within sixty (60) days after the filing thereof, 
 (iv) propose or be a party to any dissolution or liquidation,

 (v) make an assignment for the benefit of its creditors, or 

(vi) admit in writing its inability generally to pay its debts as they fall due in the general course, 

then Salix shall have the right, immediately upon written notice to Actavis and Novel, to require that Novel assume and thereafter perform any and all
obligations of Actavis under 
  
 [*] Confidential Treatment
requested; certain information omitted and filed separately with the SEC. 

  
 -33-

 
this Agreement. Upon the giving of such notice, Novel shall automatically, without further action by any Party, succeed to any and all rights, and assume and thereafter perform any and all
obligations, of Actavis under this Agreement; provided, however, that notwithstanding any such assignment, Actavis shall remain liable for its performance under this Agreement and no such assignment shall in any manner limit or impair the
obligations of Actavis hereunder. 
 (b) In the event Novel shall 

(i) file in any court or agency pursuant to any statute or regulation of any state, country or jurisdiction a petition in bankruptcy or
insolvency or for reorganization or for arrangement or for the appointment of a receiver or trustee of Novel or of its assets, 

(ii) propose a written agreement of composition or extension of its debts, 

(iii) be served with an involuntary petition against it, filed in any insolvency proceeding, and such petition shall not be dismissed
within sixty (60) days after the filing thereof, 
 (iv) propose or be a party to any dissolution or liquidation,

 (v) make an assignment for the benefit of its creditors, or 

(vi) admit in writing its inability generally to pay its debts as they fall due in the general course, 

then Salix shall have the right, immediately upon written notice to Actavis and Novel, to require that Actavis use commercially reasonable efforts to
assume and thereafter perform any and all obligations of Novel under this Agreement. Upon the giving of such notice, Actavis shall automatically, without further action by any Party, succeed to any and all rights, and assume and thereafter perform
any and all obligations, of Novel under this Agreement; provided, however, that notwithstanding any such assignment, Novel shall remain liable for its performance under this Agreement and no such assignment shall in any manner limit or impair
the obligations of Novel hereunder. In the event that Salix should invoke its rights under the preceding sentence of this Section 6.4(b), then (i) Actavis and Salix shall use their commercially reasonably efforts to effect the
qualification of Actavis (or such third party manufacturer as Actavis may propose and Salix may, in its sole but reasonable discretion, approve) to Manufacture Product not later than [*] ([*]) days following the date of Salix’s notice pursuant
to the provisions of the preceding sentence, including by (A) timely undertaking such quality and manufacturing systems reviews and audits of the relevant manufacturing facility and Actavis's or such third party manufacturer’s other
operations as are necessary or advisable in order to prepare for Actavis’s or such third party manufacturer's qualification, (B) timely making 

 
 [*] Confidential Treatment requested; certain information omitted and filed
separately with the SEC. 

  
 -34-

 
all filings and taking all such other actions as are necessary or advisable to the obtaining of all Regulatory Approvals necessary for Actavis or such third party manufacturer to Manufacture
Product hereunder, (C) timely causing to be transferred to the possession of Actavis or such third party manufacturer such of the equipment contemplated by Section 2.10(e) that is then owned by Salix as may be necessary to permit or
facilitate the Manufacture of Product by Actavis or such third party manufacturer, as the case may be, and (D) causing Novel to timely assist in this respect by providing Actavis the necessary technology transfer, data, information and other
technical assistance reasonably required by Actavis or such third party manufacturer to become qualified to Manufacture Product to be supplied hereunder (including, for the avoidance of doubt, permitting, at any time when there is reason to believe
that Novel will become the subject of any of the events described in the first sentence of this Section 6.4(b), the transfer of such technology prior to the exercise of Salix’s rights under Section 6.4(b), if reasonably requested
by Novel and Actavis); and (ii) Novel shall use its best efforts promptly to assist Salix to qualify Actavis or such third party manufacturer to Manufacture Product to meet Salix’s requirements and shall promptly grant to Actavis or such
third party manufacturer, on a royalty-free, non-exclusive basis, such licenses, and provide to Actavis or such third party manufacturer, free of charge, such technical assistance, as Actavis or such third party manufacturer may require in order to
Manufacture Product to the then-current Specifications in accordance with the then-current Manufacturing process for Product, including full technology transfer of the then-current Manufacturing processes for Product, as well as, at Salix’s
option and cost, such inventories of Materials as are necessary to effect such qualification and technology transfer and enable Salix to obtain an uninterrupted supply of Product. 

(c) In the event that Salix shall exercise or become entitled to exercise its right under Section 6.4(a) to require that Novel
assume and thereafter perform any and all obligations of Actavis under this Agreement, or under Section 6.4(b) to require that Actavis assume and thereafter perform any and all obligations of Novel under this Agreement, and the Party assuming
or to assume such obligations shall itself, before, at or after the time at which Salix exercises or becomes entitled to exercise rights as aforesaid, 
 (i) file or have filed in any court or agency pursuant to any statute or regulation of any state, country or jurisdiction a petition in bankruptcy or insolvency or for reorganization or for arrangement or
for the appointment of a receiver or trustee of Novel or of its assets, 
 (ii) propose or have proposed a written agreement of
composition or extension of its debts, 
 (iii) be served or have been served with an involuntary petition against it, filed in
any insolvency proceeding without such petition having been dismissed within sixty (60) days after the filing thereof, 
  

  

  
 (iv) propose or have
proposed or be a party or have been a party to any dissolution or liquidation, 
 (v) make or have made an assignment for the
benefit of its creditors, or 
 (vi) admit or have admitted in writing its inability generally to pay its debts as they fall
due in the general course, 
 then Salix may terminate this Agreement immediately upon notice to Actavis and Novel. 

ARTICLE VII. INDEMNIFICATION 
 7.1 Novel Indemnification. Novel shall indemnify Salix, Actavis, and their respective Affiliates and its and their respective directors, officers, employees and agents (the “Salix and
Actavis Indemnified Parties”), and defend and hold each of them harmless, from and against any and all claims, lawsuits, losses, damages, liabilities, penalties, costs and expenses (including reasonable attorneys’ fees and
disbursements) (collectively, “Losses”) incurred by any of them in connection with, arising from or occurring as a result of (a) the breach by Novel of any of its representations or warranties set forth in this Agreement,
(b) Novel’s material breach of this Agreement, (c) Novel’s negligence or willful misconduct in the performance of this Agreement, (d) the storage, release, or disposal of any hazardous or regulated material or any waste by
Novel, and (e) the enforcement by any Salix and Actavis Indemnified Party of its rights under this Section 7.1, except, in each case, for those Losses for which Salix has an obligation to indemnify the Actavis and Novel Indemnified Parties
pursuant to Section 7.2 or Actavis has an obligation to indemnify the Salix and Novel Indemnified Parties pursuant to Section 7.3, as to which Losses each Party shall indemnify the other Parties to the extent of its respective liability
for such Losses. 
 7.2 Salix Indemnification. Salix shall indemnify Actavis, Novel and their respective Affiliates, and
its and their respective directors, officers, employees and agents (the “Actavis and Novel Indemnified Parties”), and defend and hold each of them harmless, from and against any and all Losses incurred by any of them in connection
with, arising from or occurring as a result of (a) the breach by Salix of any of its representations or warranties set forth in this Agreement, (b) Salix’s material breach of this Agreement, (c) any Third Party Claim made by any
Person relating to or arising out of death, personal injury, or other product liability, related to the marketing, sale, distribution or use of the Product and caused by the product’s design or the negligence of Salix or its subcontractors,
agents or predecessors in interest, (d) any failure by Salix to maintain the Marketing Authorization so that the Specifications are in full compliance with Applicable Law or to label Product in accordance with Applicable Law (excluding any such
failure that is attributable to a breach by either Novel or Actavis of any of its representations, warranties, or other obligations 

  
 -36-

 
under this Agreement) and (e) the enforcement by any Actavis and Novel Indemnified Party of its rights under this Section 7.2, except, in each case, for those Losses for which Novel has
an obligation to indemnify the Salix and Actavis Indemnified Parties pursuant to Section 7.1 or Actavis has an obligation to indemnify Salix and Novel Indemnified Parties pursuant to Section 7.3, as to which Losses each Party shall
indemnify the other Parties to the extent of its respective liability for such Losses. 
 7.3 Actavis Indemnification.
Actavis shall indemnify Salix, Novel and their respective Affiliates, and its and their respective directors, officers, employees and agents (the “Salix and Novel Indemnified Parties”), and defend and hold each of them harmless,
from and against any and all Losses incurred by any of them in connection with, arising from or occurring as a result of (a) the breach by Actavis of any of its representations or warranties set forth in this Agreement, (b) Actavis’s
material breach of this Agreement, (c) Actavis’s negligence or willful misconduct in the performance of this Agreement, and (d) the enforcement by any Salix and Novel Indemnified Party of its rights under this Section 7.3,
except, in each case, for those Losses for which Novel has an obligation to indemnify the Salix and Actavis Indemnified Parties pursuant to Section 7.1 or Salix has an obligation to indemnify the Actavis and Novel Indemnified Parties pursuant
to Section 7.2, as to which Losses each Party shall indemnify the other Parties to the extent of its respective liability for such Losses. 
 7.4 Indemnification Procedure. 
 (a) Notice of Claim. The indemnified
party (the “Indemnified Party”) shall give the indemnifying Party (the “Indemnifying Party”) prompt written notice (an “Indemnification Claim Notice”) of any Losses or discovery of facts upon which
such Indemnified Party intends to base a request for indemnification under Section 7.1, 7.2 or 7.3, but in no event shall the Indemnifying Party be liable for any Losses that result from any delay in providing such notice. Each Indemnification
Claim Notice must contain a description of the claim and the nature and amount of such Loss (to the extent that the nature and amount of such Loss are known at such time). The Indemnified Party shall furnish promptly to the Indemnifying Party copies
of all papers and official documents received in respect of any Losses. 
 (b) Third Party Claims. The obligations of an
Indemnifying Party under this Article VII with respect to Losses arising from claims of any third Person that are subject to indemnification as provided for in Section 7.1, 7.2 or 7.3 (a “Third Party Claim”) shall be governed
by and be contingent upon the following additional terms and conditions: 
 (i) Control of Defense. At its option, the
Indemnifying Party may assume the defense of any Third Party Claim by giving written notice to the Indemnified Party within thirty (30) days after the Indemnifying Party’s receipt of an

  
 -37-

 
Indemnification Claim Notice. The assumption of the defense of a Third Party Claim by the Indemnifying Party shall not be construed as an acknowledgment that the Indemnifying Party is liable to
indemnify any Indemnified Party in respect of the Third Party Claim, nor shall it constitute a waiver by the Indemnifying Party of any defenses it may assert against any Indemnified Party’s claim for indemnification. Upon assuming the defense
of a Third Party Claim, the Indemnifying Party may appoint as lead counsel in the defense of the Third Party Claim any legal counsel selected by the Indemnifying Party, which shall be reasonably acceptable to the Indemnified Party. In the event the
Indemnifying Party assumes the defense of a Third Party Claim, the Indemnified Party shall immediately deliver to the Indemnifying Party all original notices and documents (including court papers) received by any Indemnified Party in connection with
the Third Party Claim. Subject to clause (ii) below, if the Indemnifying Party assumes the defense of a Third Party Claim, the Indemnifying Party shall not be liable to the Indemnified Party for any legal expenses subsequently incurred by such
Indemnified Party in connection with the analysis, defense or settlement of the Third Party Claim. In the event that it is ultimately determined that the Indemnifying Party is not obligated to indemnify, defend or hold harmless the Indemnified Party
from and against the Third Party Claim, the Indemnified Party shall reimburse the Indemnifying Party for any and all costs and expenses (including reasonable attorneys’ fees and costs of suit) and any Losses incurred by the Indemnifying Party
in its defense of the Third Party Claim with respect to such Indemnified Party. 
 (ii) Right to Participate in Defense.
Without limiting Section 7.4(b)(i), any Indemnified Party shall be entitled to participate in, but not control, the defense of such Third Party Claim and to employ counsel of its choice for such purpose; provided, however, that
such employment shall be at the Indemnified Party’s own expense unless (A) the employment thereof has been specifically authorized by the Indemnifying Party in writing, (B) the Indemnifying Party has failed to assume the defense and
employ counsel in accordance with Section 7.4(b)(i) (in which case the Indemnified Party shall control the defense), or (C) the interests of the Indemnified Party and the Indemnifying Party with respect to such Third Party Claim are
sufficiently adverse to prohibit the representation by the same counsel of both parties under Applicable Law, ethical rules or equitable principles. 
 (iii) Settlement. With respect to any Losses relating solely to the payment of money damages in connection with a Third Party Claim and that will not result in the Indemnified Party’s becoming
subject to injunctive or other relief or otherwise adversely affect the business of the Indemnified Party in any manner, and as to which the Indemnifying Party shall have acknowledged in writing the obligation to indemnify the Indemnified Party
hereunder, the Indemnifying Party shall have the sole right to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Loss, on such terms as the Indemnifying Party, in its sole discretion, shall deem
appropriate. With respect to all other Losses in connection with Third Party Claims, where the Indemnifying Party has assumed the defense of the Third Party Claim 

  
 -38-

 
in accordance with Section 7.4(b)(i), the Indemnifying Party shall have authority to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Loss;
provided that it obtains the prior written consent of the Indemnified Party (which consent shall not be unreasonably withheld, conditioned or delayed). The Indemnifying Party shall not be liable for any settlement or other disposition of a
Loss by an Indemnified Party that is reached without the written consent of the Indemnifying Party. Regardless of whether the Indemnifying Party chooses to defend or prosecute any Third Party Claim, no Indemnified Party shall admit any liability
with respect to, or settle, compromise or dispose of, any Third Party Claim without the prior written consent of the Indemnifying Party (which consent shall not be unreasonably withheld, conditioned or delayed). 

(iv) Cooperation. If the Indemnifying Party chooses to defend or prosecute any Third Party Claim, the Indemnified Party shall cooperate
in the defense or prosecution thereof and shall furnish such records, information and testimony, provide such witnesses and attend such conferences, discovery proceedings, hearings, trials and appeals as may be reasonably requested in connection
therewith. Such cooperation shall include access during normal business hours afforded to the Indemnifying Party to, and reasonable retention by the Indemnified Party of, records and information that are reasonably relevant to such Third Party
Claim, and making employees and agents available on a mutually convenient basis to provide additional information and explanation of any material provided hereunder, and the Indemnifying Party shall reimburse the Indemnified Party for all its
reasonable out-of-pocket expenses in connection therewith. 
 (v) Expenses. Except as provided above, the reasonable and
verifiable costs and expenses, including fees and disbursements of counsel, incurred by the Indemnified Party in connection with any Third Party Claim shall be reimbursed on a calendar quarter basis in arrears by the Indemnifying Party, without
prejudice to the Indemnifying Party’s right to contest the Indemnified Party’s right to indemnification and subject to refund in the event the Indemnifying Party is ultimately held not to be obligated to indemnify the Indemnified Party.

 7.5 Insurance. 
 (a)Each Party shall maintain (i) comprehensive general liability insurance with a combined single limit for bodily injury and property damage of not less than [*] United States Dollars ($[*]),
(ii) product liability/completed operations coverage with a per claim limit of not less than [*] United States Dollars ($[*]), and (iii) errors and omissions coverage with a per claim limit of not less than [*] United States Dollars ($[*])
(collectively, the “Policies”). If any Policy is written on a claims-made basis, the retroactive date, if any, shall not be later than the Effective Date. In addition, such coverage shall be continued in full force from such date
until the end of the Term of this Agreement and for a period of five (5) years thereafter and no Party’s Policies shall be 
  

[*] Confidential Treatment requested; certain information omitted and filed separately with the SEC. 

  
 -39-

 
canceled or subject to a reduction of coverage or any other modification without written notice to the other Parties. 
 (b) Each Party shall furnish certificates of insurance for its Policies to the other Parties within ten (10) days following the Effective Date. 

7.6 Limitation on Damages. EXCEPT WITH RESPECT TO THE GROSS NEGLIGENCE OR INTENTIONAL MISCONDUCT OF A PARTY OR BREACHES OF ARTICLE
V, NO PARTY SHALL BE LIABLE TO ANY OTHER PARTY FOR SPECIAL, PUNITIVE, INDIRECT, INCIDENTAL, EXEMPLARY OR CONSEQUENTIAL DAMAGES, INCLUDING BUSINESS INTERRUPTION OR LOST PROFITS, WHETHER IN CONTRACT, WARRANTY, NEGLIGENCE, TORT, STRICT LIABILITY OR
OTHERWISE; PROVIDED, HOWEVER, THAT THIS EXCLUSION IS NOT INTENDED TO, NOR SHALL IT, EXCLUDE DAMAGES OWED TO THIRD PARTIES. 

ARTICLE VIII. MISCELLANEOUS 
 8.1 Notices. All notices, requests and other communications hereunder must be in writing, specifically reference this Agreement in a prominent manner, and be delivered personally or by recognized
international courier to the Parties at the following addresses: 
 If to Salix to: 

Salix Pharmaceuticals, Inc. 
 1700 Perimeter Park Drive 
 Morrisville, North Carolina 27560 

Attention: AVP, Pharmaceutical Development and Manufacturing 
 with copies (which shall not constitute notice) to: 
 Salix Pharmaceuticals, Inc.

 1700 Perimeter Park Drive 
 Morrisville, North Carolina 27560 
 Attention: General Counsel 

and 

Covington & Burling LLP 
 1201 Pennsylvania Avenue, N.W. 
 Washington, D. C. 20004 

Attention: Edward C. Britton, Esq. 

  

  
 If to Novel or Actavis
to: 
 Novel Laboratories, Inc. 
 400 Campus Drive 
 Somerset, NJ 08873 

Attention: President 
 and 
 Actavis Inc. 

60 Columbia Road, Bldg. B 
 Morristown, NJ 07960 
 Attention: 

with copies (which shall not constitute notice) to: 
 Actavis Inc. 
 60 Columbia Road, Bldg. B 

Morristown, NJ 07960 
 Attention: Legal Department 
 and 

Leydig, Voit & Mayer 
 Two Prudential Plaza 
 180 N. Stetson Avenue, Suite 4900 

Chicago, IL 60601-6731 
 Attention: Steven H. Sklar, Esq. 
 All such notices, requests and other communications will
(a) if delivered personally to the address as provided in this Section, be deemed given upon receipt, and (b) if delivered by courier to the address as provided in this Section 8.1, be deemed given upon receipt. Any Party from time to
time may change its address or other information for the purpose of notices to that Party by giving notice specifying such change to the other Party hereto. 
 8.2 Force Majeure. 
 (a) Salix shall not be liable for delay or
nonperformance in whole or in part (other than a failure to pay any amount due hereunder), nor shall Actavis or Novel have the right to terminate this Agreement except as otherwise specifically provided in this Section 8.2(a), where
Salix’s performance has been affected by a condition beyond Salix’s reasonable control, including fires, floods, embargoes, shortages, epidemics, quarantines, war, acts of war (whether war be declared or not), terrorism, insurrections,

  
 -41-

 
riots, civil commotion, strikes, lockouts or other labor disturbances, acts of God or acts, omissions or delays in acting by any governmental authority; provided that if affected by such a
condition Salix shall, within [*] ([*]) days of its occurrence, give notice to Actavis and Novel stating the nature of the condition, its anticipated duration and any action being taken to avoid or minimize its effect. The suspension of performance
shall be of no greater scope and no longer duration than is reasonably required and Salix shall use commercially reasonable efforts to remedy its inability to perform. 
 (b) Actavis and Novel shall not be liable for delay in delivery or nonperformance in whole or in part (other than a failure to pay any amount due hereunder), nor shall Salix have the right to terminate
this Agreement except as otherwise specifically provided in this Section 8.2(b), where delivery or performance has been affected by a condition beyond the reasonable control of the affected Party, including fires, floods, embargoes, shortages,
epidemics, quarantines, war, acts of war (whether war be declared or not), terrorism, insurrections, riots, civil commotion, strikes, lockouts or other labor disturbances, acts of God or acts, omissions or delays in acting by any governmental
authority; provided that if either Actavis or Novel is affected by such a condition Actavis and Novel shall, within [*] ([*]) days of its occurrence, give notice to Salix stating the nature of the condition, its anticipated duration and any
action being taken to avoid or minimize its effect. The suspension of performance shall be of no greater scope and no longer duration than is reasonably required and Actavis and Novel shall use commercially reasonable efforts to remedy their
inability to perform. Notwithstanding the foregoing, in the event the suspension of performance is not attributable solely to a general shortage of Materials not unique to Novel and continues for [*] ([*]) days, and such failure to perform would
constitute a material breach of this Agreement in the absence of such force majeure event, Salix may terminate this Agreement immediately by written notice to Actavis and Novel; provided, however, that if Salix exercises its right to
terminate the Agreement as set forth in this sentence, and Actavis and Novel then, within [*] ([*]) days after such termination, regain the ability to perform their obligations under this Agreement, then Actavis and Novel may, at such time and at
its option, reinstate this Agreement and require Salix to resume purchasing Product from Actavis under the terms of this Agreement, but only at quantities up to [*] percent ([*]%) of those set forth for the applicable Calendar Years in
Section 2.2(b). 
 8.3 Entire Agreement; Amendment. 

(a)This Agreement, together with the Schedules and Exhibits attached hereto and the Settlement Agreement and the Sublicense Agreement,
sets forth and constitutes the entire agreement and understanding between the Parties with respect to the subject matter hereof and all prior agreements, understandings, promises and representations, whether written or oral, with respect thereto are
superseded by this Agreement, the Settlement Agreement, and the Sublicense Agreement. Each Party confirms that it is not relying on any representation, warranty or undertaking of any other 
  
 [*] Confidential Treatment requested; certain information omitted and filed separately with the SEC. 

  
 -42-

 
Party except as specifically set forth in this Agreement, the Settlement Agreement, or the Sublicense Agreement. 
 (b) No amendment, modification, release or discharge shall be binding upon the Parties unless in writing and duly executed by authorized representatives of both Parties. 

8.4 Further Assurances. Each Party shall duly execute and deliver, or cause to be duly executed and delivered, such further
instruments and do and cause to be done such further acts and things, including the filing of such assignments, agreements, documents and instruments as may be necessary or as any other Party may reasonably request in connection with this Agreement
or to carry out more effectively the provisions and purposes hereof or to better assure and confirm unto such other Party its rights and remedies under this Agreement. 
 8.5 Successors and Assigns. The terms and provisions hereof shall inure to the benefit of, and be binding upon, Salix, Actavis, Novel and their respective successors and permitted assigns.

 8.6 Dispute Resolution. Any dispute, controversy or claim arising out of or relating to this Agreement or the breach,
termination or validity thereof (each, a “Dispute”), shall be referred to a senior executive of each Party; provided that each such senior executive is not involved in such Dispute. Such senior executives shall meet for
attempted resolution of such Dispute by good faith negotiations within thirty (30) days after such Dispute is referred to such senior executives. If the Dispute remains unresolved after such thirty (30)-day negotiation period, then, at the
election of any Party, such Dispute shall be decided by litigation. Any such litigation shall be pursued in accordance with Section 8.7; provided that any dispute regarding the validity, scope, enforceability, inventorship or ownership
of intellectual property rights shall be submitted to a court of competent jurisdiction in the country in which such rights apply. 
 8.7 Governing Law; Jurisdiction; Venue; Service. 
 (a) This Agreement shall
be governed and interpreted in accordance with the law of the State of New York, excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another
jurisdiction. The Parties agree to exclude the application to this Agreement of the United Nations Convention on Contracts for the International Sale of Goods. 
 (b) Subject to Section 8.6, each Party irrevocably and unconditionally consents to the exclusive jurisdiction of the courts of general jurisdiction of the State of

  
 -43-

 
New York and the United States District Court for the Southern District of New York sitting in the Borough of Manhattan (collectively, the “Courts”) for any action, suit or
proceeding (other than appeals therefrom) concerning any matter arising out of or relating to this Agreement, and agrees not to commence any action, suit or proceeding (other than appeals therefrom) related thereto except in such Courts. 

(c) Each Party hereto further hereby irrevocably and unconditionally waives any objection to the laying of venue of any action, suit or
proceeding (other than appeals therefrom) arising out of or relating to this Agreement in the Courts and hereby further irrevocably and unconditionally agrees not to raise any objection at any time to the laying or maintaining of the venue of any
such action, suit or proceeding in any of such Courts, irrevocably waives any claim that such action, suit or other proceeding has been brought in an inconvenient forum and further irrevocably waives the right to object, with respect to such action,
suit or other proceeding, that such Court does not have any jurisdiction over such Party. 
 (d) Each Party hereto further
agrees that, to the maximum extent permitted by Applicable Law, service of any process, summons, notice or document by United States registered mail to its address and contact person for notices provided for in Section 8.1 shall be effective
service of process for any action, suit or proceeding brought against it under this Agreement in any of the Courts. 
 8.8
Audit; Late Payments. 
 (a)Each Party shall have the right to have an independent certified public accounting firm of
internationally recognized standing, and reasonably acceptable to the Party to be audited, provided with access by any other Party during normal business hours, and upon reasonable prior written notice, to examine only those records of such other
Party (and its Affiliates) as may be reasonably necessary to determine, with respect to any Calendar Year ending not more than [*] ([*]) years prior to the auditing Party's request, the correctness or completeness of any payment made or statement
submitted under this Agreement. Such examinations may not (i) be conducted more than once in any [*] ([*]) month period (unless a previous audit during such [*] ([*]) month period revealed an underpayment with respect to such period or an
incorrect statement submitted by the audited Party in respect of such period or the audited Party restates or revises such books and records for such period) or (ii) be repeated for any Calendar Year. Results of such audit shall (i) be
(A) limited to information relating to the Product, (B) made available to all Parties in writing, and (C) subject to Article V and (ii) not reveal any specific information of the audited Party to the auditing Party other than
(A) whether the audited Party is in compliance with its payment obligations under this Agreement or whether statements submitted by the audited Party under this Agreement are true and correct, as the case may be, and (B) the amount of any
additional payment owed to the auditing Party or excess payment reimbursable to the audited Party or any correction to statements submitted by the audited Party under this Agreement, as the case

  
 [*] Confidential
Treatment requested; certain information omitted and filed separately with the SEC. 

  
 -44-

 
may be. Except as provided below, the cost of this examination shall be borne by the [*], unless the audit reveals a variance of more than [*] percent ([*]%) from the reported amounts, in which
case the [*] shall bear the cost of the audit. Unless disputed pursuant to Section 8.8(b), if such audit concludes that additional payments were owed or that excess payments were made during such period, then the [*] shall pay the additional
amounts, with interest from the date originally due as provided in Section 8.8(c), or the [*] shall reimburse such excess payments, with interest from the date of original payment as provided in Section 8.8(c), within [*] ([*]) days after
the date on which such auditor’s written report is delivered to the Parties. 
 (b) In the event of a Dispute of any audit
under this Section 8.8, the Parties shall work in good faith to resolve the disagreement. If the Parties are unable to reach a mutually acceptable resolution of any such Dispute within thirty (30) days, the Dispute shall be resolved in
accordance with Section 8.6. 
 (c) If any payment due to a Party under this Agreement is not paid when due, then the owing
Party shall pay interest thereon (before and after any judgment) at an annual rate (but with interest accruing on a daily basis) equal to the lesser of (i) one percent (1%) per month, and (ii) the maximum rate permitted by Applicable
Law. Interest payable under this Section 8.8(c) shall run from the date upon which payment of the relevant principal sum became due through the date of payment thereof in full together with such interest. Notwithstanding the provisions of the
preceding sentence, no interest shall be payable on payments disputed in good faith or on payments in respect of Product subject to investigation under Section 2.8(d). 
 8.9 Third Party Beneficiaries. Nothing in this Agreement shall be construed as giving any Person, other than the Parties hereto and their successors and permitted assigns, any right, remedy or
claim under or in respect of this Agreement or any provision hereof. 
 8.10 Export Control. This Agreement is
made subject to any restrictions concerning the export of products or technical information from the United States or other countries that may be imposed on the Parties from time to time. Each Party agrees that it will not export, directly or
indirectly, any technical information acquired from the other Party under this Agreement or any products using such technical information to a location or in a manner that at the time of export requires an export license or other governmental
approval, without first obtaining the written consent to do so from the appropriate agency or other governmental entity in accordance with Applicable Law. 
 8.11 Assignment. 
 (a)Except as otherwise provided herein, no Party shall
have the power to assign or otherwise transfer this Agreement or any interest herein or right hereunder without the prior written consent of the other Parties, and any such purported assignment, 

 
 [*] Confidential Treatment requested; certain information omitted and filed
separately with the SEC. 

  
 -45-

 
transfer or attempt to assign or transfer any interest herein or right hereunder shall be void and of no effect. Notwithstanding the foregoing, any Party may, upon written notice to the other
Parties but without obtaining the other Parties’ consent, assign its rights and obligations under this Agreement to any of its Majority-Controlled Affiliates, to any lender providing financing to that Party or its Affiliates for collateral
security purposes, or to any successor in interest to that Party’s entire business or, in the case of Salix, to its Product business or, in the case of Novel, to its polyethylene glycol product manufacturing business, provided that
(a) notwithstanding any such assignment, such Party shall remain liable for its and its assignee’s performance under this Agreement; (b) no such assignment shall in any manner limit or impair the obligations of that Party hereunder;
and (c) following a transfer by a Party to its Majority-Controlled Affiliate, any subsequent transaction (other than one that would result in the transfer of this Agreement back to the assigning Party) that would cause such Majority-Controlled
Affiliate to cease to be a Majority-Controlled Affiliate of such Party shall be deemed to be an assignment of this Agreement requiring consent hereunder. 
 (b) If the Head License is terminated in circumstances under which Salix’s right thereunder are terminated, this Agreement, and all of Salix’s rights and remedies hereunder, may, by notice given
by Salix to Actavis and Novel, be assigned to Norgine, such assignment, however, to be subject to and conditioned upon Norgine’s execution of an instrument, in form and substance reasonably satisfactory to Actavis and Novel, agreeing to succeed
to, and to thereafter be bound by, Salix’s duties and obligations hereunder. 
 8.12 Waiver. Any term or condition
of this Agreement may be waived at any time by the Party that is entitled to the benefit thereof, but no such waiver shall be effective unless set forth in a written instrument duly executed by or on behalf of the Party waiving such term or
condition. No waiver by any Party of any term or condition of this Agreement, in any one or more instances, shall be deemed to be or construed as a waiver of the same or any other term or condition of this Agreement on any future occasion.

 8.13 Severability. If any provision of this Agreement is held to be illegal, invalid or unenforceable under any
present or future law, and if the rights or obligations of any Party under this Agreement will not be materially and adversely affected thereby, (a) such provision shall be fully severable, (b) this Agreement shall be construed and
enforced as if such illegal, invalid or unenforceable provision had never comprised a part hereof, (c) the remaining provisions of this Agreement shall remain in full force and effect and shall not be affected by the illegal, invalid or
unenforceable provision or by its severance herefrom, and (d) in lieu of such illegal, invalid or unenforceable provision, there shall be added automatically as a part of this Agreement a legal, valid and enforceable provision as similar in
terms to such illegal, invalid or unenforceable provision as may be possible and reasonably acceptable to the Parties herein. 

  
 -46-

  
 8.14 Independent
Contractors. The status of the Parties under this Agreement shall be that of independent contractors. Nothing in this Agreement is intended or shall be deemed to constitute a partnership, agency, employer, employee, or joint venture relationship
between the Parties. No Party shall have the right to enter into any agreements on behalf of any other Party, nor shall it represent to any Person that it has any such right or authority. 

8.15 Construction. Unless the context of this Agreement otherwise requires: (a) words of any gender include each other
gender; (b) words using the singular or plural number also include the plural or singular number, respectively; (c) the terms “hereof,” “herein,” “hereby” and derivative or similar words refer to this entire
Agreement; (d) the terms “Article,” “Section,” “Schedule,” “Exhibit” or “clause” refer to the specified Article, Section, Schedule, Exhibit or clause of this Agreement; (e) the term
“or” has, except where otherwise indicated, the inclusive meaning represented by the phrase “and/or”; (f) the term “including” or “includes” means “including without limitation” or
“includes without limitation”; and, (g) except where otherwise indicated, references to any agreement, instrument or other document in this Agreement refer to such agreement, instrument or other document as originally executed or, if
subsequently amended, replaced or supplemented from time to time, as so amended, replaced or supplemented and in effect at the relevant time of reference thereto. Whenever this Agreement refers to a number of days, such number shall refer to
calendar days unless Business Days are specified. The captions of this Agreement are for convenience of reference only and in no way define, describe, extend, or limit the scope or intent of this Agreement or the intent of any provision contained in
this Agreement. The language of this Agreement shall be deemed to be the language mutually chosen by the Parties and no rule of strict construction shall be applied against any Party. 

8.16 Remedies. The rights and remedies provided herein are cumulative and do not exclude any other right or remedy provided by
applicable law or otherwise available except as expressly set forth herein. 
 8.17 Counterparts; Facsimile Execution.
This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original, and all of which, taken together, shall constitute one and the same instrument. Delivery of an executed counterpart of a signature page of
this Agreement (and each amendment, modification and waiver in respect of it) by facsimile or other electronic transmission shall be as effective as delivery of a manually executed original counterpart of each such instrument. 

8.18 English Language. This Agreement shall be written and executed in, and all other communications under or in connection
with this Agreement shall be in, the English language. Any translation into any other language shall not be an official version thereof, and in the event of any 

  
 -47-

 
conflict in interpretation between the English version and such translation, the English version shall control. 
 8.19 Other Agreements. 
 (a) Simultaneously herewith, the Parties are
entering into a Settlement Agreement with Norgine. The effectiveness of this Agreement is explicitly conditioned on the simultaneous execution and delivery of the Settlement Agreement by each of the parties thereto. 

(b) Articles II and III and Section 7.5 shall become effective only upon the occurrence of the Consent Judgment Entry Date. For the
avoidance of ambiguity, in the event there is no Consent Judgment Entry Date, the provisions of Articles II and III and Section 7.5 shall never become effective. 
 [The remainder of this page has been intentionally left blank.] 

  
 -48-

  
 IN WITNESS WHEREOF,
the Parties hereto have executed this Agreement to be effective as of the Effective Date. 
  

			
	SALIX PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Carolyn J. Logan

		
	Name:	 	 Carolyn J. Logan

		
	Title:	 	 President and CEO

	
	ACTAVIS INC.
		
	By:	 	 /s/ Douglas Boothe

		
	Name:	 	 Douglas Boothe

		
	Title:	 	 CEO

	
	NOVEL LABORATORIES, INC.
		
	By:	 	 /s/ Veerappan S. Subramanian

		
	Name:	 	 Veerappan S. Subramanian

		
	Title:	 	 President and CEO

[SIGNATURE PAGE TO SUPPLY AGREEMENT] 

  
 Schedule 1.52

 Product Active Ingredients 

  
 Schedule 1.54

 Product Patents 
  

					
	Country	  	No.	  	Status
			
	USA	  	7,169,381	  	Granted
			
	USA	  	7,658,914	  	Granted

  
 -2-

  
 Schedule 1.68

 Specifications 

  
 Schedule 2.3(a)

 Non-Binding Estimate of Requirements for Calendar Year 2011 

Full year estimate for Calendar Year 2011 is [*] Units. The estimate for each month during Calendar Year 2011 is [*] of that amount. 

[*] Confidential Treatment requested; certain information omitted and filed separately with the SEC. 

  
 Schedule 2.3(c)

 Full Production Lot Sizes 
 [*] to [*] Units per lot 
 [* Confidential Treatment requested; certain information omitted and
filed separately with the SEC. 

  
 -2-

  
 Schedule 2.10(a)

 Current Capacity 
 [*] Units per year. 
 [*] Confidential Treatment requested; certain information omitted and filed
separately with the SEC. 

  
 Schedule 2.10(e)

 Anticipated Equipment Needs 
  

					
	 1.    [*]
	 		 	$[*]
	 2.    [*]
	 		 	$[*]
	 3.    [*]
	 		 	$[*]
	 4.    [*]
	 		 	$[*]
	 5.    [*]
	 		 	$[*]
		 		 	
		 	Total	 	$[*]

 [*] Confidential Treatment requested;
certain information omitted and filed separately with the SEC.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00180-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00180-of-00352.parquet"}]]